The Two Faces of Ascorbate: Prooxidant Activity and Radio-Sensitisation by Carson, Georgia
  
 
The Two Faces of Ascorbate: 
Pro-oxidant Activity and 
Radio-sensitisation 
 
 
 
 
 
 
 
 
By 
 
Georgia Carson 
 
 
 
 
A thesis 
submitted to the Victoria University of Wellington 
in fulfilment of the requirements for the degree of 
Master of Science 
 
 
 
Victoria University of Wellington 
2016 
 
 
 
 
 ii 
Acknowledgements 
My greatest, most heartfelt thanks go to Melanie McConnell for 
trusting me with this project and for always being enormously supportive, 
wise, creative and friendly.  I always felt I could ask her any question and 
this thesis would never have been completed without her immense help. I 
will be forever grateful for everything she has taught me. 
 
A huge thanks also to Leticia Castro for her in vitro technical 
training and hep with trouble-shooting, and for putting up with my 
countless questions. Leticia taught me everything I needed to know about 
cell culture and flow cytometry assays. 
 
Big thanks to Carole Grasso and Cameron Field at the Malaghan 
Institute of Medical Research, who were invaluable in teaching me all the 
in vivo work. Cam and Carole showed me intracranial surgery, mouse care 
and handling, and how to go about harvesting tumours. Big thanks also to 
the Malaghan Biomedical Research Unit staff who took great care of my 
mice and made my animal work run smoothly. 
 
I am indebted to those at Victoria University who gave me advice 
and lent me reagents along the way: Pirooz Zareie for training me on the 
flow cytometer, Nikki Templeton for the training and use of histology 
solutions and equipment, Varun Venkatesh for the SLS and IF tips, and 
Lesley Milicich for Sudan Black. 
 
Thank you also to the whole of the MMC group for being so 
supportive and making me feel part of the family: Mel, Leticia, Marie-
Sophie, Nicole, Remy, Dini, Matt, Dan, Dana, Kristal and Billy. 
 
I owe my sanity to the joke-cracking office Space Station class of 
2015L Pirooz, Matt, Sarah, Vimal and Nikki, who never failed to bring 
laughter to the long days. Thanks guys. 
 
A lot of appreciation goes to my non-university family and friends, 
who were always understanding about my long hours, and failure to return 
calls promptly. To Mum and Richard, and Dad and Donna, thanks for the 
free meals; to Hannah and Miranda, best flatmates ever; thanks Hugo for 
semi-learning how to cook and hugs; and thanks to Jess for the coffee beans 
while I was writing – much appreciated! 
 
 
 
 
 
 
 
 
 iii 
Abstract 
Although not recommended by mainstream oncologists, intravenous 
injections of pharmacological ascorbate are currently an alternative therapy 
option for cancer patients. Research has not yet determined whether high-
dose ascorbate interacts favourably with radiation therapy to increase DNA 
damage, and therefore cell death in cancer. Some studies suggest that 
ascorbate can act as a prooxidant and increase the cytotoxic effect of 
irradiation in vitro. Glioblastoma multiforme (GBM) is a primary brain 
astrocytoma that is highly therapy resistant, so patients would be 
advantaged if ascorbate radiosensitised their cancer. 
 
In this investigation, flow cytometry and single cell gel 
electrophoresis (comet tail assay) were used to measure three indicators of 
DNA damage in GBM cells in response to ascorbate and irradiation, and 
were contrasted with immunofluorescence-revealed DNA damage from an 
intracranial mouse model of GBM.  
 
The pro-oxidant, radiosensitisation role of ascorbate was confirmed, 
as measured by H2AX, 8OHdG, and DSBs in vitro. With all three of these 
markers of DNA damage, combinations of irradiation and ascorbate had 
increased damage compared with individual treatments. However 
preliminary in vivo evidence indicates that increased DNA damage did not 
occur in an animal model of GBM, and in fact ascorbate may protect from 
DNA damage in an in vivo context. 
 
These findings complement previous results from our lab, and serve 
to fill in gaps in knowledge specifically around the DNA damaging effects 
of ascorbate. The unique nature of the brain environment, as enclosed by 
the blood brain barrier, prevents translation of data from other non-brain 
cancer studies, as such, this investigation also contributes to the exploration 
of a much needed avenue of research. Considering the context of ascorbate 
treatment as a potentially harmful currently used adjuvant, it is imperative 
to confirm or disprove its efficacy in a clinically relevant environment. 
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 1 
Introduction 
 
Pharmacological levels of ascorbate, applied via intravenous 
injection, are currently an alternative therapy option for cancer patients. 
This treatment is rationalised by in vitro evidence that demonstrates 
ascorbate acts as a pro-oxidant. Although ascorbate is not part of the 
recommended course of therapeutics by mainstream oncologists, the ease of 
access and the number of alternative clinics that offer the treatment 
indicates many patients have almost certainly already integrated it with 
traditional radiation and chemotherapy. However, research has not yet 
determined whether high-dose ascorbate interacts favourably with radiation 
therapy in order to increase DNA damage and therefore cell death in 
cancerous cells. Therefore, there is a strong imperative to fully investigate 
the consequences of ascorbate in combination with radiation, and to 
determine whether its influence is beneficial, or, potentially, harmful, 
particularly in glioblastoma brain tumours, which are otherwise therapy 
resistant. The investigation detailed here confirms radiosensitisation of 
GBM cells in vitro by ascorbate, but a potential radioprotective role for 
ascorbate in vivo.  
Glioblastoma multiforme 
Glioblastoma multiforme (GBM) is the most common and 
malignant primary brain neoplasm. Derived from astrocytes, it is 
responsible for 70% of all malignant primary brain tumours (Wen and 
Kesari 2008) and 82% of malignant gliomas (Omuro and DeAngelis 2013). 
Incidence is estimated at approximately 3 per 100,000 adults per year 
(Ohgaki and Kleihues 2005; Urbanska, Sokolowska et al. 2014), although 
this varies by nation (Bondy, Scheurer et al. 2008; Omuro and DeAngelis 
2013; Wen and Kesari 2008). The cancer is more common in males and 
Caucasians (Chinot 2009) and the average age of incidence is 62 years 
(Ohgaki and Kleihues 2005). 
 
 2 
The term glioblastoma multiforme was coined in 1926 by Harvey 
Cushing and Percival Bailey; glioblastoma referencing the cancers glial, 
astrocytoma origin, while multiforme alludes to the heterogeneity caused by 
foci of necrosis and haemorrhage present in this variety of tumour 
(Greenberg, Chandler et al. 1999; Urbanska, Sokolowska et al. 2014). The 
global authority on health taxonomy, the World Health Organisation 
(WHO) classes glioblastoma multiforme (which the WHO now simply calls 
glioblastoma) as a grade four astrocytoma. This is judged by factors such as 
atypia, morphological differentiation, and degree of vascularisation and 
necrosis. Grades correspond to the malignancy of tumours such that GBM 
is the one of the most malignant, as opposed to pilocytic astrocytomas, 
diffuse astrocytomas, and anaplastic astrocytomas; grades one to three 
respectively (Louis, Ohgaki et al. 2007). 
 
There is limited conclusive evidence on the causes of GBM 
(Alifieris and Trafalis 2015; Omuro and DeAngelis 2013; Wrensch, Minn 
et al. 2002), however there are several studies that show ionising radiation 
as a significant risk factor for tumours of the central nervous system (CNS). 
For example, there is a greater prevalence of gliomas in patients that have 
received therapeutic radiation in the past for conditions such as ALL (acute 
lymphoblastic leukaemia) (Salvati, Artico et al. 1990), and survivors of the 
atomic bombing in Hiroshima showed a greater prevalence of meningioma 
(tumours of the meninges) that correlated with their distance from the 
epicentre (Shintani, Hayakawa et al. 1999). A small proportion of high-
grade gliomas can be explained by hereditary conditions such as Li-
Fraumini syndrome (a mutation of the TP53 tumour suppressor gene), 
neurofibromatosis type 1 (a mutation of the NF1 gene that negatively 
regulates the Ras pathway), or Turcot’s syndrome (mutations in DNA 
mismatch repair) (Chinot 2009; Wen, Fine et al. 1995). Furthermore, 
environmental exposure to certain metals, solvents or chemicals, especially 
those utilised in the petroleum and rubber processing industries, have been 
implicated in glioma (Spinelli, Chinot et al. 2010; Wrensch, Minn et al. 
2002). 
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There are a variety of oncogenic changes, and different 
combinations of these changes, that produce GBM (for a detailed review 
see Crespo, Vital et al. 2015). Although heterogeneous, gene alterations 
have been associated with GBM progression, such as p53 mutations, 
deletions in chromosome 10, epigenetic changes in epidermal growth factor 
receptor (EGFR) (Ohgaki, Dessen et al. 2004), and mutations in the genes 
for platelet-derived growth factor (PDGF) receptor and ligands (Verhaak, 
Hoadley et al. 2010), cyclin-dependent protein kinases (CDKs) (Nakamura, 
Watanabe et al. 2001), phosphatase and tensin homolog (PTEN) (Ohgaki, 
Dessen et al. 2004), and O6-methylguanine-DNA methyl transferase 
(MGMT) (Nakamura, Watanabe et al. 2001). Epigenetic silencing of 
MGMT is a marker of therapy responsiveness and longer survival in 
gliomas (Chinot 2009; Esteller, Garcia-Foncillas et al. 2000). 
 
GBM can be either primary or secondary. Primary cancers arise de 
novo and are most common in older adults. They are generally aggressive 
and have lower survival rates (Porter 2012). The vast majority (90%) of 
GBM is of this type (Urbanska, Sokolowska et al. 2014). Secondary cancers 
progress from lower grade tumours and thus develop over a longer time (4-
5 years) than primary tumours (Ohgaki and Kleihues 2013, Urbanska, 
Sokolowska et al. 2014). Although primary and secondary GBM are 
morphologically alike, they are genetically distinct and require a different 
therapeutic response (Crespo, Vital et al. 2015; Ohgaki and Kleihues 2013; 
Urbanska, Sokolowska et al. 2014). 
 
GBM is highly resistant to therapy, partly due to its invasive and 
heterogeneous nature (Wen and Kesari 2008). It is suggested that a 
subpopulation of cancer stem cells contributes to GBMs strong therapy 
resistance (Huang, Cheng et al. 2010), as well as hypoxia-induced cell 
survival factors and hypoxic inhibition of radiation (Legendre and Garcion 
2015). Despite a suite of treatments available, including surgery, radiation 
and chemotherapy, prognosis for GBM remains poor. Median survival is 
only 14 months, 1-year survival is less than 40%, and the 5-year survival is 
less than 5% (Omuro and DeAngelis 2013). Some population wide analyses 
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have observed even lower survival for GBM (Ohgaki and Kleihues 2005). 
This prognosis has improved minimally in the past decades, despite an 
increase in the variety of therapies (Huang, Cheng et al. 2010).  
 
There are various proposed treatments for GBM that are under 
development, including immunotherapies such as bevacizumab (anti-VEGF 
antibody) (Omuro and DeAngelis 2013), anti-VEGF gene therapy, blockade 
of NHERF-1 synthesis, and inhibition of the Mer tyrosine kinase receptor 
(Urbanska, Sokolowska et al. 2014). 
GL261 Mouse Model of GBM 
The GL261 cell line is representative of a carcinogen-induced 
mouse syngeneic glioma model (Newcomb and Zagzag 2009). Syngeneic 
models are particularly valuable to study tumour growth in vivo because, 
unlike the human xenograft models, the syngeneic models do not require a 
deficient immune system and may mimic more closely the interaction 
between tumour and immune system that takes place in human GBM 
patients. For example, in vivo tumours arising from the GL261 cell line 
have irregular, invasive borders similar to spontaneous human GBM 
tumours, rather than the clearly defined edges of xenograft, human glioma 
U87MG created tumours (Newcomb and Zagzag 2009). 
 
Seligman and Shear (1939) originally developed what would 
become GL261. Cells were derived from invasive gliomas of C3H mice 
that developed in response to pellets of 20-methylcholanthrene inserted in 
the cortex. 
 
Later, Ausman et al. (1970) propagated the line by inserting pieces 
of the original tumour into C7BL6 mice. They found GL261 to be an 
effective model for an aggressive murine glioma, with animals succumbing 
reproducibly after around 24 days subsequent to intracranial implantation. 
This study characterised the tumours based on histopathology as 
ependymoblastoma, although later investigations altered this classification 
to most similar to GBM (Newcomb and Zagzag 2009). 
 5 
 
During the 1990s, several labs reinforced this work by forming a 
permanent cell line from the gliomas (Szatmari, Lumniczky et al. 2006). 
Szatmari et al. did a thorough characterisation of the cell line, and 
discovered point mutations in the K-ras and p53 genes and expression of 
basal major histocompatibility complex (MHC) 1. GL261 was 
radiosensitive: less than 2 Gy killed half the cells in vitro and 4 Gy in mice 
slowed the progression of tumours. It was also immunogenic: vaccination 
of mice with irradiated GL261 cells 7 days before intracranial tumour 
injection inhibited cancer development in nearly all mice (Szatmari, 
Lumniczky et al. 2006). 
 
GL261 has been used extensively in vivo (and as an in vitro 
comparison), especially for pre-clinical tests (Burgi, Seuwen et al. 2014; 
Miyatake, Martuza et al. 1997; Newcomb and Zagzag 2009; Plautz, 
Touhalisky et al. 1997; Szatmari, Lumniczky et al. 2006), with nearly 40 
papers published in the last year alone utilising the model (for example 
Mathios 2016; Zhao, Jacobs et al. 2015). 
Markers of DNA Damage 
H2AX 
H2AX is a highly conserved, 14kD histone of the H2A family, one 
of the five major histone families (as well as H2A, these are H1/H5, H2B, 
H3 and H4). H2AX plays a major role in the H2A family, composing up to 
a quarter of the mammalian histone H2A’s, although this varies in different 
cell lines and tissues; as well as being crucial for recombination among 
immunoglobulin switch regions. The protein is a basal histone, thus 
synthesised during the G1 and S phase of the cell cycle (Pouliliou and 
Koukourakis 2014; Redon, Pilch et al. 2002). 
 
The phosphorylation of H2AX, H2AX is a commonly used 
indicator of double-stranded DNA breaks, as its modification is an intrinsic 
part of the DNA repair pathway (Pouliliou and Koukourakis 2014). It has 
been employed in vitro to investigate fundamental DNA repair, and in vivo 
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to study response to diagnostic irradiation (Beels, Bacher et al. 2009), as 
well as clinical response to chemotherapy and therapeutic irradiation 
(Ivashkevich, Redon et al. 2012).  
 
Traditional thought is that following DSB formation, 
phosphoinositide 3-kinase-like (PI3) proteins, especially ATM, quickly 
cause phosphorylation of the histone H2AX C-terminal tail at serine 139. 
This causes various downstream effects designed to enhance DNA repair, 
for instance, recruitment of damage sensors and repair proteins to the region 
of damage, amplification of the DNA damage response signal to ensure cell 
cycle checkpoint factors are activated, and chromatin remodelling such that 
DNA repair enzymes can access the damage more easily (Podhorecka, 
Skladanowski et al. 2010). 
 
Although it has been shown to be the case that H2AX is 
phosphorylated in response to DSBs (Rogakou, Pilch et al. 1998), for a 
number of years literature has referred to H2AX less as a marker 
specifically for double stranded breaks, and more DNA breaks, DNA 
damage response (Brumbaugh, Otterness et al. 2004; Hardee, Marciscano et 
al. 2012; Yuan, Adamski et al. 2010) or for generic genotoxic damage and 
stress (Morris, Boutell et al. 2009; Tanaka, Kurose et al. 2006). There is 
thus some doubt on whether H2AX is specific only for double-stranded 
breaks. The modification is an important part of the DNA damage response, 
but it remains possible that H2AX could be induced in response to other 
cellular events such as chromatin modelling, stalled replication, or heat 
stress (Takahashi and Ohnishi 2005; Yuan, Adamski et al. 2010). It may 
eventually be determined that these events do activate H2AX via DSBs, 
but this is yet to be clarified. In any case, it is prudent to use a variety of 
methods to further validate the presence of DNA damage varieties. 
8-hydroxy-2-deoxyguanine 
8-hydroxy-2-deoxyguanine (8-OHdG) is a modified purine, a type 
of DNA lesion caused by oxidative damage. Oxidative stress occurs at 
every moment in all cells, and because repair mechanisms are not 
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completely effective, markers of stress increase with age. 8-OHdG is 
thought to be the most mutagenic and widespread of these markers 
(Valavanidis, Vlachogianni et al. 2009). It is often used as a proxy for DNA 
damage, most commonly as a urine biomarker for general oxidative stress. 
For example, human studies have used the marker to measure effects of 
carcinogens such as tobacco and asbestos (Pilger and Rudiger 2006). In 
monocytes, the rate of 8-OhdG creation has been measured as in the region 
of 20 per 109 bases per Gy as a result of radiation (Sonntag 2006). 
 
Current estimates of steady-state levels are less than 100–1000 8-
hydroxy 2-deoxyguanosine residues in normal cells (Klungland, Rosewell 
et al. 1999). It is important to remember, however, that while oxidized 
DNA bases will impair DNA function, such bases always exist at some 
basal level, and cells have numerous repair systems to remove such species 
(Lindahl and Wood 1999). However, if they occur at critical sites, or are not 
quickly repaired, oxidized purines or pyrimidines can cause functional 
problems. As a result, oxidized DNA bases are considered an important 
event in chemical carcinogenesis (Klaunig, Xu et al. 1998). 
Comet Tail Assay 
The comet tail assay is a technique that determines the extent of 
cellular DNA damage, by measuring the distance DNA fragments travel 
from the nucleus under electrophoresis. It is so called because of the comet 
shape that the nucleoids form subsequent to application of an electric 
charge. Also known as single cell gel electrophoresis (SGE) or microgel 
electrophoresis (MGE), it was first developed by Ostling and Johanson in 
1984 to directly visualise DNA damage at the scale of individual irradiated 
cells (Ostling and Johanson 1984). 
 
Briefly, single cell suspensions are diluted in low melting point 
agarose, set on glass slides, lysed, electrophoresed, and stained for imaging. 
The rationale behind this process is that the degree of damage for each cell 
corresponds with parameters such as the length of the DNA ‘tail’ that trials 
behind the nucleoid, and the percentage of DNA in the tail; because relaxed 
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or damaged DNA travels further than wound and intact DNA. Ostling and 
Johanson determined the amount of DNA that extended out from the 
comet’s ‘head’ was proportional to the dose of radiation that cell received.  
 
There are two major categories of comet assay, the alkaline and the 
neutral. The initial experiments by Ostling and Johanson used neutral lysis 
conditions, which only allow detection of double strand breaks (DSBs). 
This is because under neutral pH, DNA base pairing is maintained, 
eliminating observation of gaps in single DNA strands. On the other hand, 
observation of single stranded breaks (SSBs) needs alkaline conditions 
(pH>12.3) that denature and unwind DNA strands (Liao, McNutt et al. 
2009). This alteration to the assay was developed a short time later (Singh, 
McCoy et al. 1988) and is now the most commonly used. Additionally, 
some sites, known as alkaline labile lesions, only become strand breaks, and 
so able to be detected, in the presence of alkali (Fairbairn and O'Neill 
1995). 
 
A strong advantage of this assay is that damage can be measured in 
individual cells, so heterogeneous responses can be identified. This is useful 
in, for example, viewing subpopulations of cells that may be unusually 
resistant compared to the whole population; other assays, such as the 
alkaline unwinding assay, only display an average damage measure. Other 
advantages include sensitivity, the requirement for low cell numbers, 
flexibility that means the comet assay can be applied to nearly all 
eukaryotic cells, and no need for specific, costly antibodies (Huycke 2003; 
Nishimura 2006; Speit and Hartmann 2006). 
 
The comet tail assay is frequently used to establish the genotoxicity 
of environmental DNA damaging agents. For example, smoking 
(Hoffmann, Hogel et al. 2005), hydrogen peroxide (Driessens, Versteyhe et 
al. 2009), environmental radiation (Tice and Strauss 1995) and other 
carcinogens (Zeljezic, Mladinic et al. 2015). The assay can also be used to 
ascertain cells response to anti-cancer agents such as radiotherapy or 
bleomycin. (Ostling and Johanson 1984). A study even used the comet tail 
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assay to look at the prooxidant effects of ascorbate and copper in 
lymphocytes (Bhat, Azmi et al. 2006). 
Radiation 
Radiation Therapy 
GBM is characterised by an infiltrating tumour mass that precludes 
clear differentiation from regular tissue and complete removal during 
surgery (Karcher, Steiner et al. 2006). Thus, as with other solid tumours, 
the standard treatment for GBM is surgery, followed by radiation therapy 
(Simpson, Horton et al. 1993), with a chemotherapy such as temozolomide 
as an adjuvant (Stupp, Mason et al. 2005). 
 
Radiation therapy is controlled energy released from the decay of a 
radioactive source, targeted to malignant regions in an attempt to eliminate 
unrestricted growth. Radiation sources for therapy generally include 
isotopes such as cobalt 60 or caesium 137 (Woods and Pikaev 1994). The 
radiation is ionising, that is, the energy is great enough that it can remove 
electrons from atoms, including those that comprise the DNA molecule. 
When this damage from irradiation becomes so great it is irreparable, the 
cell dies (Eriksson and Stigbrand 2010). 
 
Patients usually receive thirty fractions of 1.8-2.0 Gray (Gy) to a 
total of 60 Gy (Chinot 2009; Omuro and DeAngelis 2013) over around 3 to 
8 weeks (Withers 1992). 1 Gray corresponds to 1 joule per kilogram of 
mass that absorbs the radiation (Bureau International des Poids et Mesures 
2014). 
 
Before the advent of irradiation as therapy, there was evidence that 
irradiation could interfere with cellular function and survival. In the 1940s 
Euler, Hevesy, and Ahlström observed after irradiation, tagged precursors 
had inhibited incorporation into DNA, indicating irradiation prevents DNA 
synthesis (Barnum, Scheller et al. 1964). 
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Until the discovery of effective chemotherapy, irradiation was the 
only treatment that could lengthen survival in patients with high-grade 
gliomas (Chinot 2009). The effectiveness of radiation in brain cancer was 
first demonstrated by Walker et al., who extended average survival from 14 
weeks to 36 weeks by use of brain radiotherapy in high-grade gliomas. 
(Walker, Eben Alexander et al. 1978). 
 
Naturally, such a powerful treatment as irradiation has some adverse 
effects. Daily dose, total dose, and the amount of brain irradiated are factors 
that influence risk (Sheline, Wara et al. 1980). It was subsequently 
discovered that doses greater than 60 Gray unacceptably increased the 
damage to normal brain tissue (Leibel, Scott et al. 1991), accordingly a cap 
of 60 Gray is the norm (Wen and Kesari 2008). Furthermore, originally 
irradiation was applied to the whole brain to improve chances of 
eliminating tumours, however this fell out of favour when it was discovered 
that whole brain irradiation impaired brain function (Lee, Cho et al. 2012). 
Currently, irradiation is conserved to the tumour regions as much as 
possible by methods such as brachytherapy and individually shaped 
irradiation beams that minimise damage to normal tissue. 
 
Even when used correctly, irradiation causes side effects. Acute, 
delayed and late toxicity effects appear during, 2 to 3 months after, and 
over 1 year after irradiation therapy respectively (Chinot 2009). Acute 
effects are thought to be caused by oedema, delayed effects by 
demyelination, and late effects by alteration to the brain’s vascular system 
(Sheline, Wara et al. 1980). An example of late toxicity is radiation 
necrosis, which has an overall incidence of approximately 4.9% (Ruben, 
Dally et al. 2006) Radiation necrosis is injury to the peritumoural white 
matter, and is characterised by cell necrosis, vascular permeability and 
endothelial cell apoptosis, that leads to seizures and sometimes death (Siu, 
Wind et al. 2012). 
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DNA Damaging Effects of Radiation 
Experiments have shown that cytotoxicity is determined by the dose 
received by, and damage incurred by the nucleus, as opposed to the 
membrane or cytoplasm. Different types of irradiation that selectively dose 
the cytoplasm/outer membrane, nucleus, or the entire cell, indicate that 
irrespective of irradiation received by the non-nucleus regions, a nuclear 
dose of between 3 and 4 Gy is sufficient to induce LD50 levels of cell death 
(Sonntag 2006). 
 
Irradiation damage can be either indirect or direct, by ionising the 
water in the vicinity of the nucleic acid, or ionising the strand itself 
(Sonntag 2006). 
 
Indirect damage of DNA by radiolysis of the water molecules 
surrounding it is mediated by creation of the free radicals .OH, H. and eaq-. 
These reactive species can only influence DNA if they are in close 
proximity, 2 Angstroms (Ao) or fewer, for they can easily be scavenged by 
endogenous agents (Sonntag 2006).  
 
The direct effect of ionising radiation also contributes to damage 
DNA. In this case, when the irradiation reaches DNA it can ionise the 
actual DNA molecule, producing a DNA radical cation (DNA.+) and an 
electron, in addition to electronically excited DNA. This contributes to 
amplification effects that further promote damage (Sonntag 2006). 
 
Via indirect or direct means, ionising radiation causes a variety of 
types of damage, yet not all forms are created to the same degree in a given 
cell with a given dose (Table 1).
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Table 1. Types and Frequencies of Cell Damage from Irradiation 
Immediate Physical Events  
Ionizations in the cell nucleus ∼100,000 
Ionizations directly in DNA ∼2000 
Excitations directly in DNA ∼2000 
DNA Damage Effects  
SSBs  1000 
8-oxo-A (a typical single-base 
damage) 
700 
DSBs 40 
DNA−protein cross-links 150 
Whole cell effects  
Lethal events  ∼0.2–0.8 
Chromosome aberrations  ∼1 
Hprt mutations  ∼10-5 
In response to 1 Gy radiation. 
From ‘Free Radical Induced DNA and Its Repair’ (Sonntag 2006) 
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In themselves, individual lesions are not necessarily lethal to a cell. 
Even the most severe alteration, a double-stranded break, is not sufficient to 
induce cytotoxicity, despite a higher risk of misrepair because of lack of a 
template strand (Withers 1992). For example, it has been shown that an 
LD50 (50% lethal dose) in mammalian cells will produce 150 single 
stranded breaks (SSBs) and 30 double stranded breaks (DSBs), which 
demonstrates the average level of damage that can be dealt with by cellular 
repair mechanisms (Sonntag 2006). However, when this damage surpasses 
what the cell can repair, apoptosis occurs and the cell dies. 
 
DNA damage from radiation selectively affects cancerous cells 
because they reproduce more quickly, and with less quality control, than 
most normal cells. This rapid proliferation gives less opportunity for repair 
of sub-lethal damage, and so mutations are more likely to accumulate 
(Withers 1992). Cancer cells also have limited DNA repair capacity in 
relation to regular cells, because often genes associated with the DNA 
damage response (DDR) are mutated (Ciriello, Miller et al. 2013), 
prompting positive feedback where cells become more mutated (Jackson 
and Bartek 2009). 
 
However, the selectivity is not absolute or else GBM could be 
eliminated entirely with a supremely large dose of irradiation carefully 
applied to the correct area. Irradiation dosages that are capable of 
irradiating all cancerous cells are so large as to irreparably harm healthy 
tissue (Withers 1992). Additionally, there are various factors such as 
hypoxia which further alter radio-sensitivity. This fact has prompted much 
work to investigate potential radio-sensitisers that improve cancer cells 
vulnerability to irradiation while minimising effect on non-cancerous cells. 
 
One of those potential radiation sensitisers is ascorbate. 
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Ascorbate 
Ascorbate Basic Facts 
Ascorbate is more commonly known as vitamin C. Vitamins are 
naturally occurring organic molecules that the human body requires to 
function. Most have to be acquired from the environment, as they cannot be 
synthesised by humans (Australian Government Department of Health and 
Ageing National Health and Medical Research Council and New Zealand 
Ministry of Health 2006; Bendich and Deckelbaum 2015). 
Vitamins are either fat soluble, such as Vitamin A, D, and K, or 
water soluble, such as Vitamin B and C. Fat soluble vitamins can be stored 
in the liver or fatty tissue, but water soluble vitamins are excreted rapidly 
and need to be replaced (Bendich and Deckelbaum 2015). 
 
Such is the case with vitamin C. It is found in many fruits and 
vegetables (Australian Government Department of Health and Ageing 
National Health and Medical Research Council and New Zealand Ministry 
of Health 2006) and is an essential vitamin for humans, as it is an important 
co-factor in various biochemical reactions (Linster and Van Schaftingen 
2007). Humans have lost the ability to synthesise it (Burns 1957). Unlike 
most animals, Homo sapiens have no functional L-gulomo-Y-lactone 
oxidase (GLO) gene, but instead a highly mutated pseudogene. A primate 
sub-order (Pollock and Mullin 1987), guinea pigs and most bats have also 
lost the ability to synthesise ascorbate, and thus develop scurvy from 
ascorbate inadequate diets. 
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Figure 1 Biosynthesis of ascorbate 
Adapted from (Banhegyi, Braun et al. 1997) 
 
P 
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Other animals that can synthesise ascorbate via GLO convert 
glucose to L-ascorbate in the liver by the mechanism in Figure 1. The ‘L’ 
nomenclature of ‘L-ascorbic acid’ is an indication of the molecule’s 
stereochemistry (Figure 2). D-ascorbic acid, unlike L-ascorbic acid, is not 
found in nature, and lacks most of the vitamin C activity. Unless specified, 
the term ascorbate should be assumed to be ‘L-ascorbic acid’ (Crawford 
1982). 
 
Vitamin C is the general synonym for the related group of 
molecules that possess vitamin activity, that is, can prevent scurvy. 
(Australian Government Department of Health and Ageing National Health 
and Medical Research Council and New Zealand Ministry of Health 2006). 
These molecules, known as ‘vitamers’ differ depending on redox form, 
determinant on pH. (Domitrović 2006). 
 
The most reduced member of the group is ascorbic acid; however, at 
physiological pH, ascorbate, or the ascorbate monoanion, is dominant, 
owing to a first and second pKa of 4.2 and 11.6 respectively (Domitrović 
2006). When oxidised, the anion becomes an ascorbate radical, while 
further oxidation converts the compound to dehydroascorbic acid, the most 
oxidised variety (Figure 3). Note that the ascorbate monoanion is more 
commonly described with the generic descriptor ‘ascorbate’. Its monoanion 
structure enables combination with ions to create the various stable mineral 
salts of ascorbate, such as sodium ascorbate, calcium ascorbate and 
potassium ascorbate (Rose and Bode 1993). 
 
This process can also be reversed, with ascorbate radicals converted 
back to ascorbate by monodehydroascorbate reductase at the expense of 
NADH, and dehydroascorbic acid converted back into ascorbate by 
dehydroascorbate reductase at the expense of glutathione (for a detailed 
review see Noctor and Foyer 1998). This recycling in the ascorbate-
glutathione cycle is essential to mitigate ascorbate and glutathione 
consumption during their anti-oxidant function. 
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Figure 2 Stereochemical isomers L-Ascorbic Acid (L), D-Ascorbic Acid (R) 
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Figure 3. The Redox forms of Ascorbate 
Adapted from (Domitrović 2006) 
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Ascorbate as an Antioxidant 
One of ascorbate’s main roles is an effective antioxidant. In every 
cell, a finely tuned balance exists between free radicals (FRs) and reactive 
oxygen species (ROS) on one side, and antioxidants such as ascorbate, 
which counteract the harm they cause. 
 
Free radicals are molecules containing ions that have a single 
unpaired electron in the outer valence shell. This property makes them 
highly reactive. Reactive oxygen species are also highly reactive 
compounds that contain oxygen. What they have in common is a short life, 
and high reactivity with nearby molecules in order to attain stability. This 
reactivity results in other molecules becoming electronically charged, and a 
chain reaction of oxidative injury is passed on (Sonntag 2006). 
 
It should be noted the terms free radical and reactive oxygen 
species, although often used interchangeably, are not equivalent (Lushchak 
2014). Many species fall into both categories, such as the hydroxyl radical, 
OHo. However, some molecules can only be accurately labelled with one 
term, for example hydrogen peroxide (H2O2) contains oxygen but no 
radical. 
 
Both FRs and ROS are a natural product of biology and not merely 
harmful. Reactive oxygen species are produced from normal metabolising 
mitochondria (complexes I and II), and neutrophils use them to kill 
pathogens. They can also regulate gene expression (Palmer and Paulson 
1997; Sen and Packer 1996), relay intracellular signals (Colavitti, Pani et al. 
2002; Fatma, Kubo et al. 2005), and activate important factors such as 
hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor 
(VEGF) (Liu, Hu et al. 2006; Xia, Meng et al. 2007). 
 
However, an increase in the normal number of FRs or ROS causes 
oxidative stress, when the abilities of the antioxidant defence system are 
outweighed by the destructive oxidants (Varjovi, Valizadeh et al. 2015). 
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During this imbalance, important molecules such as lipids, proteins and 
DNA are harmed. Depending on the extent and type of stress, this state can 
be very destructive, and has been linked to pathologies such as 
atherosclerosis, as well as more general processes such as inflammation, 
neurodegeneration, ageing and carcinogenesis (Emerit, Edeas et al. 2004). 
 
Antioxidants can be either enzymatic such as superoxide dismutase 
(SOD) or catalase, or non-enzymatic and consumed, such as ascorbate. 
Non-enzymatic antioxidants are capable of neutralising free radicals 
because they are easily able to forfeit an electron to balance radicals, while 
not themselves becoming reactive, although some antioxidants transiently 
become radicals which are then regenerated by other antioxidants (for 
example vitamin E (a-tocopherol) is regenerated by vitamin C (Cooke, 
Evans et al. 2003). This process minimises damage and keeps radicals in 
check. 
 
Ascorbate is well known to act as a potent scavenger of FRs and 
ROS (Dutta, Gautam et al. 2015), and by the same mechanism, reduce 
metal ions (Englard and Seifter 1986). Along with glutathione, ascorbate is 
arguably the most significant non-enzymatic antioxidant in a physiological 
context. Its structure allows easy contribution of either one or two electrons 
to radical compounds, while not becoming reactive itself (Bielski, Richter 
et al. 1975) by resonance stabilisation of the unpaired electron in the 
ascorbyl radical (Figure 4), or dismutation to ascorbate or DHA (Buettner 
and Jurkiewicz 1996). Further, DHA is recycled in the ascorbate-
glutathione cycle to regenerate the original antioxidant. 
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Figure 4. Resonance Stabilisation of the Ascorbyl Radical  
Adapted from (Carr and Frei 1999) 
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Ascorbate as a Co-factor 
Another function of ascorbate is as a co-factor in various reactions. 
Ascorbate acts as a co-factor for a large and diverse family of enzymes 
known as the Fe and 2-oxoglutarate dependent dioxygenases, enzymes that 
also rely on co-substrate 2-oxoglutarate and a catalytic iron site to bring 
about hydroxylation of their respective substrate (Kuiper and Vissers 2014; 
Meredith and May 2013; Rebouche 1991). Three subgroups of these 
enzymes with relevance to cancer are the enzymes that hydroxylate 
collagen, HIF1, and 5-methylcytosine. 
Collagen 
The best known co-factor role for ascorbate is participating in 
collagen synthesis and prevention of scurvy. Scurvy only occurs in animals 
unable to produce the active enzyme L-gulonolactone oxidase that have 
insufficient ascorbate intake. Lack of ascorbate leads to incomplete 
hydroxylation of collagen, thus dysfunctional synthesis of the molecule, 
and symptoms such as swollen gums and poor wound healing. If the 
deficiency is not corrected, the eventual outcome is death. Most animals, 
excluding primates, guinea pigs, and fruit bats, are resistant to this disease, 
as they are able to undergo de novo ascorbate synthesis in the liver 
(Carpenter 1988). 
 
In what has been called one of the first examples of a controlled 
trial, in the 18th century British naval surgeon James Lind rediscovered and 
popularised the solution that foods high in vitamin C, such as citrus, had 
antiscorbutic properties. Since Albert Szent-Gyorgyi successfully isolated 
the ascorbic acid molecule in 1928 (Carpenter 1988), science has learnt the 
mechanism by which ascorbate has this effect. Specifically, ascorbate acts 
as an essential co-factor of lysyl and prolyl hydroxylase, two important 
enzymes that catalyse the hydroxylation of their respective amino acids in 
collagen biosynthesis (Figure 5). Without ascorbate, hydroxylation of the 
residues, and therefore the correct structure of the collagen chains cannot 
occur, resulting in a weakened final molecule (Myllylä, Kuutti-Savolainen 
et al. 1978). 
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The biosynthesis of collagen is dose dependent on the concentration 
of ascorbate available, with each molecule of ascorbate corresponding to 
addition of one hydroxyl to the collagen. This reaction oxidises the 
ascorbate molecule to DHA, and occurs at an early stage in collagen 
synthesis, in the rough endoplasmic reticulum (RER), before glycosylation 
(Vonk, Doulabi et al. 2010). 
HIF1-a 
Another enzyme ascorbate acts as a cofactor for is hypoxia 
inducible factor 1 (HIF-1) (Kuiper 2012). HIF1 is a transcription factor key 
to a cells response to hypoxia, or low oxygen conditions. Hypoxia is toxic 
to cells in general, yet it also provokes a plethora of responses that alter the 
way they function to promote survival, for instance changing from aerobic 
to anaerobic metabolism, glycolysis and transport of glucose, and 
encouraging factors such as vascular endothelial growth factor (VEGF) in 
order to increase angiogenesis and therefore blood supply and oxygen 
(Kuiper 2012; Ziello, Jovin et al. 2007). 
 
HIF1 exists as a heterodimer consisting of HIF1-α and HIF1-β; both 
are expressed constitutively, although under normoxic conditions HIF1-α is 
rapidly degraded and the dimer cannot be formed. In this situation of 
normal oxygen, prolyl hydroxylase domain-containing proteins (PHDs) 
hydroxylate specific prolines in HIF1a’s oxygen-dependent degradation 
domain, causing it to associate with the von Hippel Lindau (VHL) tumour 
suppressor protein. In turn, E3 ubiquitin protein ligase recognizes VHL and 
targets HIF-1α for degradation. Another hydroxylase, factor inhibiting 
HIF1 (FIH-1), can block HIF1 from interacting with its target genes during 
normoxia by modifying a particular asparagine residue (Kuiper, Dachs et al. 
2014). 
 
Conversely, under hypoxic conditions, the process of degradation is 
prevented by inactivation of PHDs and FIH1, and HIF1a can accumulate. It 
translocates to the nucleus to dimerise with HIF1b and activate their many 
target genes. The targets of HIF1 include tumour relevant genes such as 
growth factors that encourage angiogenesis and cell proliferation (Kuiper 
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and Vissers 2014), and genes that instigate the de-differentiation process 
epithelial mesenchymal transition (EMT) (Zhang, Huang et al. 2013). 
 
In the context of cancer, hypoxia and HIF1 are very important. All 
solid tumours will have regions of hypoxia because of insufficient 
vascularisation. Hypoxia is also associated with resistance to irradiation and 
chemotherapy, and thus poor survival outcomes (Zhao, Quan et al. 2015). 
The HIF1 transcription factor promotes cell proliferation and survival, 
clearly fundamental processes to cancer development. 
 
As ascorbate is a crucial cofactor for the activity of HIF1 
hydroxylases, PHD and FIH1, ascorbate supplementation can inhibit HIF1, 
and so regulate its many downstream targets. Ascorbate can even 
counteract prevention of hydroxylase action by a number of hydroxylase 
inhibitors. This is thought to be principally via maintaining the iron domain 
of the two hydroxylases in the reduced state, and the effect is more 
pronounced for FIH1 than PHD (Kuiper, Dachs et al. 2014).  
 
This has been borne out by experimental evidence. Firstly, the 
amount of ascorbate in human tumour tissue negatively correlates with 
HIF1 activation (Kuiper and Vissers 2014) as well as tumour phenotype 
and disease-free survival (Kuiper, Dachs et al. 2014). GULO mice that had 
ascorbate supplementation in their drinking water also displayed lower 
expression of HIF1 target genes, and decreased melanoma and lung cancer 
growth. (Campbell, Vissers et al. 2015). A xenograft study with mice that 
had been inoculated with cells that expressed a stable (i.e. constitutively 
active) form of HIF1 reported that ascorbate supplementation could not 
inhibit the tumour growth of these mutant HIF1 lymphoma, yet it could 
inhibit the activity of regular wild type HIF1 (Gao, Zhang et al. 2007). 
 
Therefore, supplementation with ascorbate may be expected to lead 
to decrease of functional HIF1, and thus less hypoxia-dependent tumour 
cell proliferation and therapy resistance, and thus less hypoxia-dependent 
tumour cell proliferation and therapy resistance. 
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5-methylcytosine 
5 methylcytosine (5mc) is a DNA nucleotide, a cytosine, modified 
by a methyl group. Epigenetic modification of core DNA sequence by 
groups such as methyl residues is a large area of research, because these 
changes cause alterations in the way genes are expressed. As is the case 
with methylcytosines, which are involved in mammalian development and 
stem cell differentiation, among other functions (Tahiliani, Koh et al. 2009; 
Wu and Zhang 2011). 
 
Ten eleven translocation (TET) methylcytosine deoxygenases (1-3) 
are the enzymes that catalase the addition of a hydroxyl group to 5mc, 
modifying it to 5 hydroxymethylcytosine (5hmc). This is the first step in a 
process that ultimately demethylates the cytosine, altering any downstream 
epigenetic that would have otherwise occurred. 
 
Interestingly, there may be a synergistic effect between HIF1 and 
TET. In tumorigenic neuroblastoma cells, hypoxia caused activation of 
HIF1, which in turn upregulated the expression of TET (Mariani, 
Vasanthakumar et al. 2014). 
 
TET enzymes and their 5mc substrate also have relevance to cancer 
development. Abnormal methylation in general is strongly associated with 
cancer. Further, there is a marked lack of hydroxylated 5mc in cancerous 
cells relative to regular cells, although it is not yet clear whether this is 
symptomatic or causal (Ficz, Branco et al. 2011). Thus, enzymatic 
methylation modifiers such as TET have been implicated in oncogenic 
development (Wu and Zhang 2011). 
 
It has been shown that ascorbate plays a co-factor role in TET 
activity (Minor, Court et al. 2013). By acting as an essential co-factor for 
TET, again thought to be primarily by maintaining the catalytic iron in a 
reduced state, it enhances the creation of 5hmC and alters its epigenetic 
action. For example, mouse fibroblasts cultured in ascorbate free medium 
have far less 5hmc than usually, but when ascorbate is added, levels of 
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5hmc increase in a dose dependent manner. This is dependent on the 
presence of functioning ascorbate transporters, and does not occur with 
other antioxidants. The mechanism is mediated by TET, as when TET is 
blocked with shRNA, the action of ascorbate is obstructed (Dickson, 
Gustafson et al. 2013). 
 
In summary, ascorbate has been shown to function as a co-factor for 
a range of enzymes, and it is likely more interactions will be uncovered in 
the future. These connections have wide ranging consequences, not all of 
which have yet been determined.  
 
However, ascorbate has been postulated to function in yet another way that 
has consequences for cancer therapy; as a prooxidant. 
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Figure 5. Ascorbate acts as a co-factor in the hydroxylation of proline in the biosynthesis of 
collagen 
Adapted from (Division of Life Sciences 2011)  
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Ascorbate as a Prooxidant: The Fenton and Haber-Weiss reaction 
Ascorbate’s role as a pro-oxidant was discovered relatively recently, 
compared to its ability to act as an antioxidant or co-factor. As such, less is 
known about the details and caveats to its action. But there is biological 
basis to suspect ascorbate is capable of exhibiting pro-oxidant properties. In 
high doses ascorbate could help overwhelm cancer cells and improve 
cancer outcomes. The proposed mechanism is the Fenton and Haber-Weiss 
reactions. 
 
The Fenton reaction describes the general process of a reduced 
metal and an oxidant becoming an oxidised metal and an even stronger 
oxidant (Wardman and Candeias 1996). In his original paper to Chemical 
Letters, Henry John Horstmon Fenton described the formation of a violet 
coloured product (dihydroxymaleic acid) from tartaric acid (reductant), 
hydrogen peroxide (oxidant), and ferrous sulphate (catalytic metal source). 
The metal and oxidant used to explain the equation are iron and hydrogen 
peroxide, although other transition metals and oxidants can undergo the 
process. Fenton never investigated the mechanism behind the reaction that 
was named for him, he only used it as a tool in reactions. 
 
The Haber-Weiss reaction built on Fenton’s work, and was 
published in the 1930s. It provided a mechanism for creation of hydroxyl 
radicals from hydrogen peroxide and the superoxide ion (Haber and Weiss 
1934). This reaction happens naturally, albeit slowly, in cells, yet the 
presence of transition metals can catalyse it and thus increase the rate. This 
Haber-Weiss reaction makes use of Fenton chemistry in Eq3. 
 
O-. + H+ + H2O2    O2 + H2O + .OH Eq 1 (Net Haber-Weiss) 
 
 
O-. + Fe3+   Fe2+ + O2  Eq 2 
 
Fe2+ + H2O2   Fe3+ + -OH + .OH Eq 3 (Fenton Reaction) 
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Hydrogen peroxide for the Fenton reaction can be from a range of 
sources, such as the dismutation of superoxide by SOD, or leakage from 
respiration in the mitochondria. 
 
The significance of the formula took some time to be recognised 
(Wardman and Candeias 1996). At the time, it was thought that free 
radicals could not occur in vivo. And because the net Haber-Weiss reaction 
is thermodynamically unfavourable it needs a catalyst to have large effects. 
Eventually the role of transition metals in fulfilling the catalysis role, and 
the significant biological action potential was recognised. This reaction is 
commonly known as the iron or metal catalysed Haber-Weiss reaction, or 
the superoxide driven Fenton reaction. 
 
Although the most common representation of the Fenton and Haber-
Weiss reaction, the formulas above are not the only example of this type of 
reaction. For example, the Fenton reaction can easily proceed with nitric 
oxide (NO) or a superoxide ion in the place of a transition metal to produce 
hydroxyl radicals. 
 
Ascorbic acid can stand in for the superoxide ion in Part 1 of the 
Haber-Weiss reaction. This still achieves the redox active transition metal 
in Eq 5 required for Fenton chemistry in Eq 6: 
 
AA + H+ + H2O2 AA. + H2O + .OH Eq 4 (Net Haber- 
                                                     Weiss) 
 
 
AA + Fe3+   Fe2+ + AA. + H+  Eq 5 
 
Fe2+ + H2O2   Fe3+ + -OH + .OH  Eq 6 (Fenton Reaction) 
 
Another alternative is that the reduced metal produced in Haber-
Weiss Part 1 goes on to react with molecular oxygen and create hydrogen 
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peroxide. This was the model proposed by Chen et al. (2008) in order to 
explain how high doses of ascorbate could act as a prodrug, and deliver 
hydrogen peroxide to the extracellular fluid, rather than the blood where the 
relatively higher concentrations of catalase would degrade hydrogen 
peroxide rapidly: 
 
Fe2+ + 2O2   Fe3+ 2O2-.   Eq 7 
 
2O2-. + 2H+  O2 + H2O2   Eq 8 
 
All of these reactions feed into each other, for example hydrogen peroxide 
can then go on to react with another reduced transition metal as in Eq 3, and 
create a hydroxyl radical (Parrow, Leshin et al. 2013). 
 
These equations that show ascorbate’s potential to create ROS is significant 
Hydrogen peroxide has a range of deleterious effects, being able to attack 
DNA, lipids in membranes, glucose metabolism and proteins. Yet hydroxyl 
radicals, created from the superoxide molecule in Eq 3, and from ascorbate 
in Eq 6, are even more deleterious to cell components when not detoxed by 
antioxidants. The hydroxyl radical is considered the most aggressive ROS, 
as it is the most reactive (Nappi and Vass 2000). It can be reduced and still 
be considered a ROS (H2O2). However, the hydroxyl radical has a very 
short half-life, a nanosecond compared to on the order of minutes for 
hydrogen peroxide (Sonntag 2006), and so can only influence its immediate 
vicinity. 
 
These reactive oxygen species produced by ascorbate, as with irradiation, 
produce a variety of types of DNA damage. 
Ascorbate Transport  
Although humans often consume a moderate amount of ascorbate 
from various sources in their diet, characteristics of the transporters that 
facilitate uptake contribute to relatively low serum levels, at least compared 
with other, ascorbate synthesizing species. 
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Normally, ascorbate enters the human body through diet, and thus 
through epithelial cells of the small intestine. It then enters the circulatory 
system by diffusing through capillaries. Once in the kidney, ascorbate is 
transferred via the glomerulus capillary bed to the Bowmans capsule and 
from there taken up into renal epithelial cells. The body retains only what is 
reabsorbed in this manner, and excess proportions will be excreted in the 
urine (Ball 2008). This naturally limits the potential ascorbate serum 
concentration attainable. 
 
Ascorbate is polar and relatively large, meaning it cannot readily 
diffuse across cell membranes and must be actively transported into cells, 
or transferred through facilitated diffusion. Ascorbate is transported via 
substrate transporters, either sodium dependent vitamin c transporters 
(SVCT1 and 2), or glucose transporter (GLUT) isoforms, depending on the 
redox form it takes (either ascorbic acid or DHA), and what tissue it is in 
(Rumsey, Kwon et al. 1997). Expression of these transporters varies by 
tissue type (Table 2). SVCT transporters utilize active transport in concert 
with sodium, while GLUT transporters employ facilitated diffusion. 
 
SVCT 1 and 2 have high specificity for ascorbic acid compared with 
a very low affinity for DHA, and so will effectively only transport 
ascorbate in the ascorbic acid form. In contrast, GLUT transporters will 
only transport DHA, in addition to their traditional role as glucose 
transporters (Rivas, Zuniga et al. 2008; Rumsey, Kwon et al. 1997; Vera, 
Rivas et al. 1993) 
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Table 2. Ascorbate Transporters 
Sodium 
dependent 
active 
transport 
SVCT1 Found in 
epithelial 
tissue 
Transports 
ascorbic 
acid with 
higher 
capacity 
Role key for 
 Intestinal 
absorption 
 renal 
reabsorption 
 liver 
accumulation. 
KO mice = 
excessive 
urinary 
excretion of 
AA 
Sodium 
dependent 
active 
transport 
SVCT2 Found in 
brain (low 
levels 
elsewhere) 
Transports 
ascorbic 
acid with 
higher 
affinity 
Main transporter in: 
 Brain 
 Pituitary 
 Adrenals 
 Pancreas 
KO mice die 
immediately 
after birth of 
brain 
haemorrhage 
and 
respiratory 
failure. 
SVCT1 and 2 have individual functionality, yet high sequence homology. 
Sodium 
independent 
facilitated 
diffusion 
GLUT-
1/2/3/4 
Found 
throughout 
the body in 
most cells 
Transports 
DHA and 
glucose (a 
hexose 
transporter) 
GLUT1 
 Endothelial 
tissue 
 Blood brain 
barrier 
GLUT3 
 Neuronal 
Both 
 Osteoblast 
 Muscle 
 Retinal 
KO causes 
many 
systemic 
abnormalities: 
 
Growth, 
adipose, 
cardiac, liver, 
gut issues 
(e.g. Faconi-
Bickel, De 
Vivo 
diseases).  
SVCT info from (Tsukaguchi, Tokui et al. 1999); GLUT info from (Olson and Pessin 
1996; Pascual, Wang et al. 2004) 
 
Although GLUT transporters carry ascorbate like SVCT 
transporters, they predominantly deal with glucose transport. This is 
because of the higher incidence of glucose than DHA, and the resulting 
competitive inhibition of DHA uptake. SVCT transporters are also more 
influential due to greater affinity for ascorbic acid than GLUT for DHA, as 
well as the large ascorbic acid to DHA ratio present throughout the body 
(Li, Chen et al. 2011). The severe ascorbate deficiency effects caused by 
knockout of SVCT transporters is evidence of their importance over GLUT 
transporters, especially for specific organs such as the brain. (Parrow, 
Leshin et al. 2013) However, in cells where only GLUT transporters are 
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expressed, cells have no choice but to rely on them for their ascorbate needs 
(Agus, Gambhir et al. 1997). 
 
In the CNS, astrocytes and neurons collaborate utilising both types 
of transporters to maintain ascorbate and thus redox homeostasis. This is 
despite ascorbic acid not being able to pass through the blood brain barrier 
and instead requiring conversion to DHA to allow transport before being 
reduced back (Agus, Gambhir et al. 1997). Under conditions of oxidative 
stress, DHA accumulates, as ascorbic acid is oxidised during detoxification 
of ROS. Astrocytes lack SVCT so cannot uptake AA like neurons. 
However, astrocytes contribute by uptake of DHA via GLUT1, reduction to 
ascorbic acid via glutathione (which they possess in relative abundance), 
and release for neurons to uptake. Reduction of dehydroascorbic acid can 
only happen inside cells (in endoplasmic reticulum). Neurons also express 
GLUT transporters so could carry out reduction of DHA themselves, 
however their antioxidant capacity is less than that for astrocytes (Garcia-
Krauss, Ferrada et al. 2015). 
 
Transport of ascorbate specifically to tumour tissue has been 
investigated. It is well known that cancer patients have much reduced 
systemic ascorbate concentrations (World Cancer Research Fund 2007). 
Yet this does not necessarily translate into tumour tissue, for instance, brain 
tumours have less ascorbate, but other tumours such as breast and lung have 
been shown to have more ascorbate. It is not yet known ascorbate scarcity 
in tumours is owing to insufficient vascularisation, or alterations in the 
expression of SVCT transporters. Intriguingly, the ascorbate concentration 
of tumour tissue has been shown to correlate with disease free survival in 
some tumours (Kuiper, Dachs et al. 2014). 
 
Ascorbate Pharmacokinetics  
One of the reasons ascorbate was neglected for so long as a possible 
anti-cancer therapeutic is is because the vast difference the mode of 
application makes, specifically oral or intravenous, was not appreciated 
(Padayatty, Sun et al. 2004). 
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The SVCT2 transporters are easily saturatable. The Km value range, 
depending on cell type and pH is 65–237 µM for SVCT1 and 8–62 µM for 
SVCT2 (Savini, Rossi et al. 2008). This indicates higher concentrations will 
not be taken up by the SVCT transporters. This particularly applies to the 
intestines during oral delivery. 
 
The total body pool of ascorbate is generally 1.5-2 grams, yet the 
levels of ascorbate vary throughout the body (Kallner, Hartmann et al. 
1979). Ordinarily, the brain, especially the pituitary gland, and the adrenal 
medulla have the highest levels (Patak, Willenberg et al. 2004). 
 
The ascorbate serum concentration can range from ~6 to 92 µM, 
depending on an individual’s typical intake (Levine, Conry-Cantilena et al. 
1996). A recent pharmacokinetic model predicted normal tissue under 
average serum ascorbate concentrations would produce extracellular 
concentrations of around 20 to 50µM, and intracellular concentrations of 
between around 300 and 700µM (Kuiper, Vissers et al. 2014). Some 
specific cells may contain higher concentrations, such as neutrophils and 
leukocytes, which have up to 30 times greater ascorbate than a typical cell, 
in order to protect themselves from the ROS they use to destroy pathogens 
(Wang, Russo et al. 1997). 
 
One hundred milligrams of ascorbate orally daily are enough to 
saturate the body in healthy individuals, as indicated by leukocyte 
concentrations and the appearance of urinary excretion. This amount is 
enough to generate a fasting plasma concentration of approximately 60 µM, 
yet increasing the dosage by a factor of 10 to 1000 mg daily can only 
produce 75-80 µM. Oral doses even greater than this cannot generally 
increase plasma concentration further (Levine, Conry-Cantilena et al. 1996; 
Padayatty and Levine 2001; Padayatty, Sun et al. 2004). The higher end of 
this plasma concentration scale, around 80 µM, has been reported as ideal 
to reach tissue saturation (Kuiper, Vissers et al. 2014).  
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Ascorbate concentration in plasma follows a sigmoid function 
(Levine, Conry-Cantilena et al. 1996; Newton, Morgan et al. 1983). 
Newton et al. found that plasma concentrations plateau at the renal 
threshold of 80 μM. Levine et al. demonstrated that the steep portion of the 
concentration curve came about with doses between 30 and 100 mg and that 
complete saturation transpired at 1,000 mg daily. For comparison, the 
current New Zealand recommended dietary intake for vitamin C ranges 
from 45 to 85 mg/day, with a “prudent limit” of 100mg/day (Australian 
Government Department of Health and Ageing National Health and 
Medical Research Council and New Zealand Ministry of Health 2006). 
 
Physiological half-life of ascorbate is dependent on the blood 
concentration and whether ascorbate is plentiful. In periods of deficiency, 
renal transporters actively uptake ascorbate to prevent excretion. In this 
situation, at levels lower than around 85µM, half-life is inversely 
proportional to concentration, while only above 85 µM does half-life 
become constant, on average 14.2 days. In contrast, when ascorbate intake 
is high and concentration spikes, excretion is swiftly increased and half-life 
is greatly decreased to in the region of 30 minutes (Levine, Padayatty et al. 
2011). 
 
An additional limit to ascorbate intake is that transporters are down 
regulated in response to ascorbate itself. This negative feedback occurs at 
the level of translation and decreases uptake when consumption increases. 
Above 1g/day intake can drop to lower than 50% of even normal absorption 
(Kallner, Hartmann et al. 1979). These characteristics significantly limit the 
amount of ascorbate that can be derived orally. 
 
Absorption is further altered by portioning of ascorbate quantities. 
There is evidence that fractionating dosages can increase the absorption 
such that smaller individual doses given several times per day can increase 
serum concentration more than one larger dose daily. (Australian 
Government Department of Health and Ageing National Health and 
Medical Research Council and New Zealand Ministry of Health 2006) 
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However, these limitations are overcome when ascorbate is applied 
intravenously. 0.1 to 1.0 grams per kilogram of body mass gives peak 
concentrations over 10 mM, and Riordan et al. detailed how an infusion of 
up to 115g over 8 hours in patients produced prolonged plasma 
concentrations of up to 5mM (Mikirova, Casciari et al. 2013). A single 
infusion intravenously of 1.25g gives plasma concentration ~7 times higher 
than could be achieved with that same dose orally. Pharmacokinetic 
modelling has also attempted to predict potential plasma concentrations 
achievable with ever greater intravenous infusions. For example, it is 
predicted that 100g intravenous infusion would transiently reach a 
concentration of nearly 20mM, dwarfing the micromolar concentration that 
comes from the maximally tolerated oral dose of 18 grams per day 
(Padayatty, Sun et al. 2004). 
 
This differentiation in ascorbate concentration is key. Intravenous 
delivery results in much higher systemic ascorbate concentrations, and it is 
only these high concentrations that can exhibit pro-oxidant effects capable 
of destroying cancer cells. 
 
In short, there are multiple examples of ascorbate causing DNA 
damage, especially when in culture with transition metals (Halliwell and 
Gutteridge 1986). There is also substantial evidence of the ability of 
intravenous application of ascorbate in vivo to reach the concentration 
capable of inducing pro-oxidant effects in vitro. Yet, whether this translates 
to effective cytotoxicity of cancerous cells, and, more importantly, selective 
therapeutic benefit in vivo is far from settled. 
Ascorbate as Disease Therapy 
While ascorbate definitively prevents scurvy, there is controversy 
over the effectiveness of the antioxidant role of ascorbate in preventing 
diseases other than scurvy. For example, Linus Pauling, the only person to 
win two unshared Nobel Prizes, suggested that large doses of ascorbate are 
capable of preventing or significantly reducing the symptoms and duration 
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of the common cold. Subsequent studies found some positive effects, 
although a recent Cochrane meta-analysis concluded that, “The lack of 
effect of regularly administered vitamin C on the incidence of the common 
cold in the general population throws doubt on the usefulness of this 
practice […] It does not seem worthwhile to carry out further regular 
supplementation trials in the general population.” However, the writers did 
allow that the small positive effects seen, combined with the low cost of 
regular ascorbate supplementation, indicated that it may be worthwhile for 
cold-prone and especially athletic individuals to experiment with ascorbate 
supplementation of 1-2 grams/day (Hemila and Chalker 2013).   
 
The potential mechanism of action proposed to explain the mild 
benefit of ascorbate against the common cold is as an immune stimulator. 
Ascorbate both enhances T-cell proliferation, a key white blood cell 
member of the immune system, and decreases apoptosis (Naidu 2003). 
 
Other studies have investigated ascorbate’s effectiveness in 
preventing atherosclerosis and cardiovascular disease. The ARIC 
(Atherosclerosis Risk in Communities) study reported subjects older than 
55 had a statistically significant inverse relationship between Vitamin C 
intake and average carotid intima media thickness, an indicator of 
atherosclerosis progression. While analysis of epidemiological data relating 
to heart health found that higher vitamin C/vitamin E ratio correlates with 
lower risk of CVD (Gey 1998). 
Ascorbate as Cancer Therapy 
There is epidemiologic evidence of the positive preventative anti-
cancer effects of antioxidant ascorbate. Development of cancer, especially 
age-related, is caused in part by oxidative damage to DNA. There is 
overwhelming support that a diet high in fruits and vegetables decreases the 
risk of cancer (Lunet, Valbuena et al. 2007; World Cancer Research Fund 
2007), and there are some studies that show this may be specifically due to 
the ascorbate content (Halliwell 2001; Loria, Klag et al. 2000). Some 
populations whose consume large amounts of ascorbate have a decreased 
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risk of some types of cancer (Gey 1998). For example, there is a correlation 
between eating foods high in ascorbate and lower risk for stomach cancer, 
cervical cancer, and oesophageal cancer (Block 1991; Bo, Lu et al. 2015), 
although results are not conclusive (Bjelakovic, Nikolova et al. 2004; 
World Cancer Research Fund 2007 ), and this does not appear to be 
generalizable to all forms of cancer (Gaziano, Glynn et al. 2009; Head 
1998; Lin, Cook et al. 2009; Miura and Green 2015). 
 
Despite its traditional role as an antioxidant, ascorbate has been 
investigated as a cancer therapy that is effective through pro-oxidant means. 
However, when scientists first formed the theory of ascorbate’s anti-cancer 
effect, it was the role in collagen creation that was the proposed 
mechanism, as its prooxidant capacity had not been learned. Today, both 
functions are thought to contribute to potential effectiveness.  
 
A US doctor, William J. McCormick, first developed the theory that 
ascorbate may potentially decrease the incidence of cancer in the 1950s. He 
thought cancer was an ascorbate deficiency disease and improving collagen 
with supplemental ascorbate could prevent it. His previous work claimed to 
show that very large doses of ascorbate had antibiotic effects against 
tuberculosis, scarlet fever and other infectious diseases when administered 
intravenously or intramuscularly (McCormick 1952). 
 
McCormick synthesised several strands of information to produce 
his theory. In two papers that were published in Archives of Paediatrics 
(McCormick 1954; McCormick 1959), McCormick explained how he 
believed cancer could prevent and treat cancer at early stages. At the time, 
the extent of knowledge surrounding the cause of cancer was limited to the 
hypothesis that it was a combination of “chronic irritation” such as that 
caused by soot inhalation, coupled with a removal of restraints on cell 
growth (McCormick 1954). He noticed that cancer is characterised by 
extensive uncontrolled growth and metastases, and that at the time (as 
now), the medical community’s focus was on medicinal and surgical 
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treatments, rather than prevention or examining the impact of metabolism 
and diet. 
 
By the time McCormick was formulating his theory, ascorbate’s 
function as a collagen, and in fact general connective tissue reinforcer was 
well known. Furthermore, it was widespread knowledge that cancer patients 
had much lower ascorbate serum concentrations than healthy individuals, 
even accounting for their sub-par nutrition. 
 
McCormick stressed how the basement membrane, which contains 
collagen, is a key boundary for metastasising cells, and if that boundary was 
to be breached, or ineffectually repaired, the potential for tumours and 
metastasis is greatly increased. Further, connective tissue is another barrier 
to metastasis, and because it too consists of collagen, it could be 
strengthened by ascorbate (McCormick 1954). 
 
With this information regarding ascorbate’s abilities to both 
reinforce connective tissue and inhibit the destruction of connective tissue, 
McCormick hypothesised that the primary cause of cancer development 
was a lack of ascorbate that in turn caused weakened connective tissue and 
allowed rogue cells to subvert their constraints. He was the first to propose 
the link between a lack of ascorbate and a predisposition to cancer. 
Although he didn’t carry out any practical studies to demonstrate the 
validity of his idea, his theory would open the door to later scientists who 
attempted to uncover whether ascorbate did indeed improve cancer 
outcomes. 
 
As well as strengthening the barriers to metastasis, ascorbate was 
found to inhibit the molecules that break down these barriers. Another 
component of the extracellular environment is hyaluronic acid, the simplest 
glycosaminoglycan in the extracellular matrix. Karl Meyer and John Palmer 
discovered hyaluronic acid isolated from the vitreous of bovine eyes in the 
1930s (Selyanin, Boykov et al. 2015).  
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Break-down of hyaluronic acid enables metastasis, and 
hyaluronidase is the enzyme cancer cells use to break down hyaluronic acid 
to do so. As early as the 1950s, Reppert, Donegan and Hines (Reppert, 
Donegan et al. 1951) showed that ascorbate could effectively inhibit 
hyaluronidase’s catabolic effect on hyaluronic acid. More recently it has 
been reported that L-ascorbic acid, D-isoascorbic acid and DHA can all 
inhibit hyaluronidase (Okorukwu and Vercruysse 2003) and ascorbic acid 
derivatives can also obstruct the function of the enzyme, to a much greater 
degree than the parent compound. (Spickenreither, Braun et al. 2006) 
 
Inspired by the theories that had been published, Scottish physicians 
Ewan Cameron and Allen Campbell produced one of the first trials of high 
dose ascorbate in 1974. This particular trial aimed to treat patients that had 
been judged ‘untreatable’ and had not received conventional therapy, 
although they had previously been treating many patients, including some 
that had traditional therapy in conjunction with high-dose ascorbate 
(Cameron, Campbell et al. 1975). 
 
50 cancer patients took 10g of ascorbate per day for the initial 10 
days intravenously, and orally thereafter, while some took only oral 
ascorbate. The doses were fractionated into 2.5g of ascorbate four times 
daily. Interestingly, Cameron and Campbell note in their report that they 
believe in hindsight that intravenous administration is “probably 
unnecessary”, except in cases where for some reason the patient is unable to 
consume ascorbate orally (Cameron, Campbell et al. 1975). 
 
Cameron and Campbell reported a large variety of responses within 
their 50 patients, ranging from no response, to growth retardation, to 
tumour necrosis. Of course due to the lack of controls in this particular 
study, no statistical inferences could be made, yet they claimed that a 
subjective evaluation clearly showed the patients survived “longer than 
reasonable clinical expectation.” However, there were some promising 
measures regarding factors such as quality of life and erythrocyte 
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sedimentation, which they compared with an “expected trend” (Cameron, 
Campbell et al. 1975). 
 
Later that decade, Cameron collaborated with the prestigious Nobel 
Prize winner Linus Pauling on a larger scale trial (Cameron and Pauling 
1979). As mentioned previously, Pauling had already been promoting the 
notion of high-doses of ascorbate as a therapy for the common cold (see 
‘Ascorbate as an Antioxidant’). 
 
A series of terminal cancer patients were treated in 1976. In this 
study, detailed in two papers published in the Proceedings of the National 
Academy of Sciences (PNAS), Cameron and Pauling set forth how 100 
again ‘untreatable’ cancer patients (50 of whom were reported on 
previously) were given ascorbate and compared with 1,000 matched 
controls from the same hospital. Their protocol was based on the previous 
trial, with patients receiving both intravenous and orally administered 
ascorbate (Cameron and Pauling 1976). 
 
Pauling and Cameron found longer survival times with ascorbate 
than “what would be expected”. The mean survival time for ascorbate-
treated patients was over 160 days longer than that of the matched controls, 
who only survived on average 50 days after being deemed untreatable. 
There was even decreased tumour growth and cases of tumour regression. 
In a large proportion of ascorbate treated patients, survival was determined 
to be 4 times greater than control patients, while in 10% of ascorbate treated 
patients their survival was even more significantly lengthened such that a 
number were still alive when the paper was published. Pauling and 
Cameron did not go so far as to proclaim this proportion ‘cured’, but 
estimated their survival to be approximately 20 times greater than the 
control group. The report measured survival only, and did not consider 
other parameters such as quality of life. The scientists were influenced by 
McCormick’s investigations and proposed the increase in survival was due 
to enhanced collagen production and ‘restrained’ cancerous cells rather than 
outright killing (Cameron and Pauling 1976). 
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However, there were significant problems with the Cameron and 
Pauling trials. For instance, there was no genuine control group. 
Retrospective controls were used, such that patients treated with ascorbate 
were compared with past patients that, from their medical records, had 
apparently similar levels of disease. An independent reviewer carried out 
the matching, yet the trial could not be double-blinded or placebo 
controlled. 
 
This, and other aspects of the trial brought understandable criticism 
(Creagan, Moertel et al. 1979). Some questioned the reliability of the 
decision to pronounce patients untreatable, as it was in Pauling’s interest to 
include those that were less ill in the treatment arm, thus artificially 
lengthening the overall survival for this group. Whether the sample and 
control group were truly representative subpopulations was another doubt 
raised by detractors. 
 
The pair’s second trial attempted to correct some of this criticism. 
For instance, controls were re-selected, taking extra care to match as 
accurately as possible to the treatment group for cancer type, sex, and age. 
Furthermore, they carried out statistical tests to determine the time between 
date of admission to the hospital and date deemed ‘untreatable’; if the 
control and treatment groups were matched accurately, these times should 
be similar for the two groups. Instead of diluting the apparent effectiveness 
of high-dose ascorbate, this updated analysis strengthened its ostensible 
potential. The ascorbate-treated patients had a mean survival time 
approximately 300 days greater than controls. Survival times longer than a 
year being deemed untreatable were observed for 22% of the ascorbate-
treated patients compared with only 0.4% of the controls (Cameron and 
Pauling 1976). 
 
Yet critics were not satisfied (Comroe 1978). The essence of the 
trials as non- blinded nor controlled by placebo left much to be desired; as 
well as the fact that only 10 new ascorbate treated patients had been 
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replaced, and half of the controls had been drawn from the first study. 
Furthermore, Pauling and Cameron appeared to have a rather unscientific 
faith in the molecule’s efficacy. In Cancer and Vitamin C, published in 
1979, Cameron said that “he did not feel justified in carrying out a 
randomized, double-blind trial because he was convinced of the value of the 
vitamin for his patients, and it would therefore be unethical to withhold it 
from those who would be serving as controls." (Carpenter 1988) 
 
In response to the controversy, the Mayo Clinic undertook two 
double blind, randomised, placebo-controlled studies involving patients 
with advanced cancer. The studies, reported in 1979 (n=150) and 1985 
(n=100), found that patients given 10g of vitamin C daily did no better than 
those given a placebo. 
 
In the first report only a small proportion of their subjects had not 
previously received therapy. There was no difference between the treated 
and control groups in age, sex, previous therapy, type of primary tumour, or 
ECOG (Eastern Cooperative Oncology Group) score. Survival rates 
between the two groups were so similar that the curves overlapped, and 
there were also no statistically significant differences in symptoms 
(Creagan, Moertel et al. 1979). 
 
Their second paper attempted to contend Pauling’s objection that 
the cause of the negative results in the first study was due to the patients’ 
previous chemotherapy. The Mayo authors contested that if in fact 
ascorbate was incompatible with chemotherapy then there was no choice 
but to opt for the proven chemotherapy over an unproven vitamin (Richards 
1988). Despite this argument, and to appease Pauling and his high-profile 
supporters, a second trial was performed (Richards 1988). They randomised 
100 patients with advanced colorectal cancer, none of whom had received 
prior chemotherapy and 4 of whom had received radiation, into control and 
treatment groups. Again, patients were stratified by various parameters and 
again, no statistically significant differences were found between the two 
groups in survival and symptoms. It seemed that the theory of high-dose 
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ascorbate in treating cancer had been invalidated (Moertel, Fleming et al. 
1985). 
 
In the face of this new evidence, the National Cancer Institute Panel 
determined that there was "insufficient evidence” for high-doses of 
ascorbate as a cancer therapy (Richards 1988). However, in both of these 
trials, ascorbate was only given orally, a fact not commented upon by the 
authors. 
Ascorbate as a Prooxidant Cancer Therapy 
Since investigation into the particular pharmacokinetic processes 
that regulate ascorbate, and the discovery of its capacity to act as a 
prooxidant, a multitude of studies have investigated the possibility of large 
doses of the molecule causing antitumor effects. 
 
Despite the lack of conclusive evidence regarding its effectiveness, 
the use of high-dose ascorbate as a cancer therapy is increasing, prompted 
by the large number of orthomolecular healthcare practitioners who 
dispense it (Padayatty, Sun et al. 2010). These health providers 
predominantly sit at the periphery of mainstream science based medicine, 
but are well served by a clientele of patients interested in ‘holistic health’, 
including vitamin products (Richards 1988). A large advantage accentuated 
by the proponents of ascorbate as an anticancer treatment is its low toxicity. 
Ascorbate, even in very high doses, is generally well tolerated (Cameron, 
Pauling et al. 1979). 
 
Yet overall, in the scientific literature, there seems to be a general 
consensus that ascorbate treatment alone has no significant effect on the 
development of tumours in vivo, (and therefore any possible effect would 
only be due to interaction with radiation or chemotherapy) (Kurbacher, 
Wagner et al. 1996). Even Pauling and Cameron intended for high-dose 
ascorbate to be used as an adjuvant therapy to increase the body’s defences 
to cancer, while traditional therapy attacked it. 
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 In Vitro Trials 
A wealth of trials exists on the effect of ascorbate on cancerous cells 
in vitro, whether as a monotherapy, or in combination with traditional 
therapies such as chemotherapy or radiation. The majority of studies that 
investigate ascorbate and cancer appraise pancreatic, ovarian, or breast 
cancer (Du, Martin et al. 2010; Kurbacher, Wagner et al. 1996; Ma, 
Chapman et al. 2014). Despite this extensive literature, and in consideration 
of the focus of this investigation and the unique environment of the brain, 
only in vitro studies that considered brain cells, and especially glioblastoma 
multiforme, will be overviewed.  
 
Laurenzi et al. (1995) only reported cell death of SK-N-BE(2) 
neuroblastoma cells in response to either 10 nm – 1 mM of ascorbate, or 1-
5 mM of hydrogen peroxide (the mechanism by which ascorbate has its 
prooxidant effect, see ‘Ascorbate as a Prooxidant’). They found 32% and 
43% cell fatality in response to hydrogen peroxide and ascorbate 
respectively. Interestingly, this was much less than that observed with 
melanoma cells under the same conditions, where over 80% of cells died. 
The mechanism of this cytotoxicity was apoptosis, or programmed cell 
death. 
 
A large set of cell lines were assessed by Chen et al. (2008) to 
confirm ascorbate’s prooxidant effect and cytotoxicity. In all, 43 types of 
cancerous cells and 5 normal cell varieties were evaluated, including a 
murine neuroblastoma (2a), 3 kinds of rat GBM (C6, 9L, RG2), and nine 
human GBM cell lines. Survival, indicated by EC50 was measured and 
reported, indicating several interesting outcomes. As the authors expected, 
none of the non-cancerous cell lines displayed cytotoxicity in response to 
even the highest ascorbate dose of 20mM. As for the cancer lines, there was 
a great variation in the cell survival, even amongst GBM only. For instance, 
the murine neuroblastoma, the rat GBM, and one of the human GBM lines 
(S635) had an EC50 of less than 1mM. The remaining GBM cell lines EC50 
ranged from less than 5mM (LN229 and A172) to U383 and U87, which 
appeared impervious to even 20mM of ascorbate. A subsequent catalase 
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test with a subgroup of the cell lines indicated that ascorbate cytotoxicity 
was mediated by hydrogen peroxide. 
 
Thomas et al. (Thomas, Vezyraki et al. 2005) investigated the effect 
of ascorbate on various cancer cell lines in the context of cell cycle 
analysis. They published that although 2mM of ascorbate or DHA could 
induce significant death in HeLa (cervical adenocarcinoma) cells, 
concentrations up to 5mM had very little effect on the GBM cell line T98G. 
However, it could delay activation of Cdc2 and entry of cells into mitosis. 
This result was in contrast to Chen et al.’s findings in the previously 
mentioned study, where a 2-hour ascorbate treatment followed by a 24- 48-
hour recovery period resulted in an EC50 of around 8mM. A 48-hour 
treatment in 5mM, such as that used by Thomas et al, could be expected to 
have decreased viability at least somewhat, yet no concentration below 
5mM decreased viability more than 20%. This may indicate that at least for 
this particular GBM cell line, an effective concentration for cell death only 
arises at doses between 5mM and 8mM, or alternatively, some particulars 
of protocol influenced the efficacy of ascorbate on this cell line between the 
two experiments. 
 
The GBM cell line T98G were also studied by Naidu et al. (Naidu, 
Tang et al. 2001), who treated them with small concentrations (1-175µM) 
of a lipophilic ascorbate derivative, ascorbyl stearate, for 24 hours. This 
caused cells to accumulate at S/G2-M, inhibited clonogenicity and 
proliferation, and induced apoptosis. The authors postulated that these 
ascorbate effects were mediated either by creation of ascorbyl radicals, or 
by decrease in insulin-like growth factor I receptor (IGF-IR), because 
ascorbate dose and time dependently modulated the expression of IGF-I, an 
important regulator of the cell cycle. In this case, mechanism of action may 
not have been via prooxidant activity, but this was not determined by the 
authors, as no catalase assays or the like were carried out. The same authors 
also investigated the effect of ascorbyl stearate and ascorbyl palmitate on a 
murine glioma line, G-26, and again found that both ascorbate derivatives 
dose-dependently decreased proliferation and viability of cells. It is 
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interesting to note the heightened anti-proliferation potency ascorbate 
derivatives compared with ascorbate alone, although they are less studied 
than their parent molecule and so safety is less assured, they are generally 
considered to be non-toxic (Elmore 2005). 
 
In contrast, some studies have investigated the potential for 
ascorbate to act in concert with other therapies. 
 
Allen et al. (2012) investigated the effect of radiation in 
combination with ascorbate on the U87 line, another GBM derived cell. 2-
5mM of ascorbate in the cell media caused cytotoxicity and radio-
sensitization in U87 cells. The cytotoxicity and radio-sensitization was 
inhibited by catalase and by metal chelators, indicating the importance of 
metal catalysis and supporting hydrogen peroxide as the key mediator of 
oxidant activity. The effect was the same in non-small cell lung carcinoma 
cells. 
 
In our own lab, a number of papers have outlined the prooxidant 
capacity of ascorbate in vitro (Castro, McConnell et al. 2014; Grasso, Fabre 
et al. 2014; Herst, Broadley et al. 2012). Human GBM cell lines and 
primary GBM cells, a human glial cell line, and primary human vascular 
endothelial cells as well as the murine equivalent of GBM, GL261 (see 
‘GL261 Mouse Model of GBM’) and regular astrocytes (C8D1A) have 
been used. We have also investigated the effect of ascorbate damage in 
concert with the traditional therapy radiation. 
 
Viability in response to treatments was measured via trypan blue 
exclusion. As expected, normal astrocytes were found more resistant to 
radiation than cancerous cells. Human cell lines and late passage primary 
cells were the next resistant, while early passage primary cells and the 
murine GBM cells were the least resistant to radiation relatively. 
 
Ascorbate addition to radiation treatment increased its effectiveness. 
1 Gy of irradiation did not decrease cell viability a great deal; cells were 85-
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90% viable for primary cells and 75% in the most radiosensitive GL261 
cells, yet a sub-lethal dose of ascorbate, only 0.5mM, could decrease cell 
viability to 70-80% and 50% for primary cells and GL261 respectively. 
Similarly, the level of DSBs, as indicated in proxy by the appearance of 
H2AX, appears synergistically increased by combination treatments as 
opposed to monotherapies.  
 
Significantly, GBM primary cells, the most relevant in vitro 
representation of in situ tumours, underwent greater than additive decreases 
in viability when treated with both therapies, potentially signposting a 
synergistic effect for ascorbate and radiation treatment in vivo. 
 
Herst et al. showed that although both 5mM of ascorbate and 6Gy of 
irradiation damaged primary GBM cells, combination treatment generated 
significantly more harm, and killed more cells than individual treatments. 
GBM cell lines were also radio-sensitised by addition of ascorbate in Castro 
et al., but although this effect was consistent among the cell lines, 
variability was high with regards to the degree each cell line could be 
radiosensitised. Cell lines also varied in response to individual treatments; 
in some cell lines, treatment with ascorbate caused more DSBs than 
irradiation. 
 
When originally comparing murine astrocytoma and astrocytes, we 
found the normal cells were less affected by the addition of ascorbate than 
cancerous cells, a promising finding for potential therapy which indicated 
specificity for the treatment. However, in a more recent paper, normal 
untransformed glial cells fared no better than GBM cells in the effect of 
treatment on DNA damage, repair, viability, and clonogenicity. Both GBM 
cells and normal cells (SVGp12, a normal glial cell line and HUVEC, a 
vascular endothelial cell line) were harmed equally by the oxidative stress 
caused by radiation and/or ascorbate.  
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The GBM, SVGp12 and HUVEC cell lines have additionally been 
investigated for their antioxidant capacity, in recognition of the probably 
prooxidant mechanism of ascorbate. Cell lines differed in their basal 
antioxidant ability. The degree of antioxidant in a given GBM cell line will 
influence the amount of ROS produced in that cell from a given dose of 
ascorbate, and, interestingly, has been reported to correlate with the ability 
of the cell to repair damage, as measured by the resolution of the H2AX 
signal. 
 
The effectiveness of combination treatments in GBM primary cells 
was dose dependent on both ascorbate and irradiation. As measured by cell 
viability, sub-lethal ascorbate doses of 0.5mM increased the cytotoxic 
effect of irradiation 2-fold, yet when added at 5mM, the effect was 
increased 4-fold. In a similar way, the cytotoxicity of 6Gy of irradiation 
could be increased 5-fold by addition of the smaller concentration, while a 
full 5mM increased cell death 10-fold. 
 
Cell cycle analysis was also investigated using DNA content 
analysis. It was determined that irradiation only resulted in G2/M arrest in 
GBM cells, but that addition of ascorbate could prevent this arrest. It was 
later discovered that ascorbate caused accumulation in S phase. This is 
significant therapeutically, because cell cycle arrest is a method of allowing 
DNA damage to be repaired, and thus limits the ability of irradiation to 
provoke damage induced cell death. If ascorbate can prevent the cell cycle 
blockade and DNA repair, it bodes well for ascorbate increasing the 
effectiveness of irradiation, complementary to the pro-oxidant effect. 
 
The mechanism of ascorbate damage is certainly H2O2 mediated, for 
catalase mostly abrogated the effect of ascorbate, yet the precise pathway of 
cell death with these treatments is not yet determined. Herst et al. showed 
that the cytotoxic effect in GBM was not mediated by either apoptosis or 
autophagy. 
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In conclusion, GBM in vitro studies indicate several important 
points. Firstly, ascorbate is capable of acting as a prooxidant in GBM cells 
in vitro. Secondly, there is much variation between cell lines, even amongst 
purportedly the same type of cancer. It cannot be assumed that one GBM 
cell line will react in the same way as others, so individual cell line tests 
will provide much needed information. Thirdly, some data suggest a useful 
distinction in vulnerability between normal and cancer cells, yet this must 
be further confirmed if ascorbate is to become a viable potential treatment. 
In Vivo Animal Model Trials 
Far fewer in vivo studies than in vitro have been carried out on the 
effect of ascorbate on cancer. Although a handful of in vivo studies have 
investigated the effect of oral ascorbate only on reducing tumours or 
improving other cancer outcomes (Varga and Airoldi 1983), these trials will 
not be discussed here, due to the tightly regulated pharmacokinetics and the 
conclusion that they cannot reach pharmacological concentrations. Oral 
ascorbate could potentially be effective in other capacities, such as 
immuno-stimulation and increasing the strength of extracellular matrix, yet 
it is not sufficient to reach the levels capable of incurring prooxidant 
activity. 
 
Many of the following studies utilised intraperitoneal injections in 
animals to simulate intravenous dosing in humans. The mode of delivery 
influences the specific uptake of ascorbate, as has been already discussed, 
yet reports have validated this substitution with pharmacokinetic modelling. 
Chen et al. (2008) reported that in gavage (oral) dosing of rats, the pattern 
of ascorbate concentration over time mirrored that of intestinal absorption 
in humans. Further, intravenous administration of the same dose caused an 
80-fold higher concentration of ascorbate, approximately 8mM, and 
intraperitoneal injections caused, at the highest peak, a 30-fold increase on 
gavage concentration. Although intravenous and intraperitoneal 
administration caused differing initial peak serum concentration, within 20 
minutes the intravenous concentration stabilised, and the two methods 
followed a similar time/concentration pattern, albeit with intravenous 
delivery remaining slightly higher until the 90-minute time point. Thus, it 
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can be assumed that this method of delivery in mice is approximately 
equivalent to the intravenous infusions used in human studies. 
 
Although the focus of this project is GBM, much more of the 
informative studies have been carried out in pancreatic models. There are 
several examples here of ascorbate successfully acting in a prooxidant role 
in this model. However, caution should be applied when considering the 
translation of pancreatic cancer to GBM, which is in a significantly 
different microenvironment. 
 
Recently, Fukui et al. (Fukui, Yamabe et al. 2015) published 
evidence that ascorbate alone could decrease tumour growth in a nude 
mouse model of pancreatic cancer via strong oxidative stress, followed by 
an activation of proteins associated with autophagy and eventually cell 
death. The group discovered that, in line with their in vitro work involving 
MIA-PaCa-2 cells, an established pancreatic cancer model, nu/nu mice that 
were inoculated with these cells and then underwent thrice weekly 
ascorbate intraperitoneal injections from 3 weeks subsequently, had 
“significantly suppressed tumour growth and tumour weight.”  
 
GBM xenografts were treated with irradiation (2x 6 Gy), 
chemotherapy (5mg/kg temozolomide), and ascorbate (2-5mM) by Allen et 
al. Mice treated with both irradiation and chemotherapy had unsurprisingly 
longer survival than control, untreated mice, yet it was reported that the 
addition of ascorbate to the regimen could decrease tumour growth and so 
increase survival, in this case. Mice that received ascorbate in addition to 
traditional therapies for their GBM xenographs lived on average 2 weeks 
longer than mice that received only irradiation and chemotherapy. 
 
Chen et al. used pancreatic murine xenographs to investigate the 
effect of ascorbate in combination with the other traditional antioxidant 
glutathione (Chen, Stone et al. 2011). They reported that 4g/kg of ascorbate 
daily reduced tumour volume by nearly half. Although all treatments, 
ascorbate, glutathione, and combination treatments improved survival 
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compared to control mice, glutathione in fact abrogated the effectiveness of 
ascorbate alone, indicating a competitiveness between the two traditional 
antioxidants that is in stark contrast to their synergistic function outlined 
earlier. 
 
The McConnell group’s most recent paper (Grasso, Fabre et al. 
2014) used a standard dose of irradiation in combination with ascorbate 
(5mM), and showed that pre-treatment with ascorbate for 1-hour radio-
sensitized the murine GL261 cells, as indicated by survival and clonogenic 
assays in vitro. However, in C57BL/6 mice with intracranial GL261 tumour 
cells, this radio-sensitising function of ascorbate was reversed. 
 
Irradiation only mice were treated with a single dose of 4.5 Gy to 
the brain 8 days post intracranial surgery, ascorbate only mice received 
ascorbate daily via intraperitoneal injection from day 8 to day 45 after 
surgery, and the combined treatment mice received both treatments. 
 
Although irradiation alone increased survival time, as expected, 
ascorbate only treated mice survived no longer than the control group. Most 
interestingly, the group of mice that received both treatments had in fact 
shorter survival than those that were given irradiation only. Histological 
analysis reported less tumour necrosis in this group also.  
 
Essentially, ascorbate had inhibited the anti-tumorigenic effect of 
irradiation, indicating a potential, and dangerous radio-protective role. 
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Aims 
The overall aim of this thesis was to determine whether ascorbate 
has prooxidant effect in a brain tumour model in vivo. This research builds 
on previous work in our lab that demonstrates radiosensitisation of tumour 
cells in vitro by ascorbate, but expands knowledge by looking at a variety 
of specific DNA damage indicators in this process. Although survival has 
been assessed in in vivo GL261 models of ascorbate’s interaction with 
irradiation in GBM, analysis of effects on DNA has not yet been 
determined, and so will be examined in this study. 
 
In order to achieve this, the following specific objectives were 
proposed. 
 
The first objective was to confirm the prooxidant activity on the in 
vitro GL261 model, and to determine the precise mode of DNA damage. 
 
The second objective was to use a murine intracranial glioma model 
to investigate whether ascorbate led to the same DNA damage in vivo. 
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Methods 
Materials 
Cell culture plastic consumables were purchased from In Vitro 
Technologies (Auckland, New Zealand); cell culture reagents were from 
Life Technologies (Carlsbad, CA., USA). Sodium ascorbate and other 
chemicals were from Sigma (St. Louis, MO., USA). 
Cell Lines 
The mouse GBM cell line, GL261, was from the NCI tumour cell 
line repository (Fredrick, MD., USA). Immortalized human GBM cell lines 
(LN18, T98G) were from the ATCC (Manassas, VA., USA). Primary GBM 
cell lines (NZG 1003, NZG 0809), were cultured from tumour tissue from 
patients undergoing debulking surgery, as previously described in Hunn, 
Farrand et al. 2012. 
Cell Culture 
Cells were kept in cell culture flasks, stored in incubators (Sanyo 
MCO-20AIC CO2 Incubator) set to 37oC, under 5% CO2 and 95% 
humidity.  
Media 
DMEM (for GL261 cells), supplemented with: 
500mL DMEM 
50mL FCS (to=~9% v/v) 
5mL Glutamax (To =~1% v/v) 
RPMI-1640 (for T98G, LN18, 1003, and 0809 cells), supplemented 
with: 
500mL RPMI-1640 
30mL FCS (to=~5.6% v/v) 
Treatments 
Ascorbate 
 Dehydrated sodium ascorbate 
 Diluted in PBS to a 1.5M working solution 
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 Added to final concentration of 5mM 
 
Hydrogen Peroxide 
 Stock solution 7.23M 
 Diluted in PBS to a 7.23mM working solution 
 Added to final concentration of 500 µM 
Irradiation 
Cells were irradiated with Cesium-137 gamma-rays (Gammacell 
3000 Elan, Best Theratronics) for the required time for a given dose. 1 
minute of irradiation corresponded to approximately 4.2 Gy, with slight 
variation over the course of the year as the radiation source lost potency. 
DNA Damage Analysis 
Flow Cytometry 
In this investigation, the process for assessing the degree of H2AX 
and 8-OHdG in cells between treatment groups was similar. Aside from 
different antibodies, the only other difference was the requirement of 
secondary 488 conjugated antibodies when measuring 8-OHdG. 
 
GL261, 1003, or T98G cells were plated at 3x104 cells per well in 6-
well plates. 3 wells of each 6-well plate were assigned to treatment 
conditions, either control, ascorbate, irradiation, hydrogen peroxide, or both 
ascorbate and irradiation. The next day, 24 prior to treatment, media was 
removed from wells and replaced with fresh media. Cells were 
approximately 40% confluent and growing exponentially when treated. 
 
Cells were treated with ascorbate to a total concentration of 5mM 
for 60 minutes. Dehydrated ascorbate was diluted with PBS (Dulbecco’s 
Phosphate Buffer Saline, 1.4M NaCl, 27mM KCl, 170mM NaH2PO4, 
17.6mM KH2PO4) fresh for each experiment. 7.23M stock hydrogen 
peroxide was diluted with PBS and added to wells for a final concentration 
of 500µM. 
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60 minutes after ascorbate or hydrogen peroxide treatment of cells, 
media was aspirated from wells and plates were irradiated for 1 minute and 
25 or 26 seconds, for a final dosage of 6 Gy, or longer depending on dosage 
required.  
 
For anti-H2AX antibody assays, wells were replaced with fresh 
media and kept in an incubator set to 37oC for a further 60 minutes before 
beginning harvest. Cells were fixed at 180 minutes’ post-irradiation. In the 
case of anti-8-OHdG assays, cells were harvested immediately post-
irradiation in order to complete fixation within 60 minutes of irradiation 
treatment. 
 
To harvest cells for flow cytometry analysis, wells were aspirated, 
rinsed with PBS, and incubated with 1mL of TE for 4 minutes at 37oC. TE 
was quenched with 2mLs of media and cells were collected in 15mL Falcon 
tubes, spun for 5 minutes at 500g in a centrifuge (Gryozen 1580MGR), and 
distributed with 200 μL of PBS into a round bottomed 96 well plate. Cells 
were washed in PBS with 1% BSA (FACs buffer), and then fixed with 100 
μL of FoxP3 fixative for 30 minutes at 4oC. After fixation, cells were spun 
for 8 minutes at 800g, washed twice in 200 μL of BD Perm/Wash buffer, 
incubated at 4oC for 15 minutes, before being pelleted and resuspended in 
50 μL of the required concentration of antibody solution at 4oC overnight. 
 
For anti-H2AX antibody assays, antibody (Alexa Fluor® 488 anti-
H2A.X-Phosphorylated [Ser139] 2F3 Clone, mouse IgG1 isotype, 
Biolegend) was diluted in BD Perm/Wash at a ratio of 1:150 (stock 
concentration 25ug/mL, working concentration 166.7ng/mL). 
Approximately 15 hours later, antibody was removed, cells were again 
washed twice in BD Perm/Wash buffer and resuspended in 300 μL of FACs 
buffer for flow cytometry analysis; 
 
For anti-8-OhdG assays, primary antibody (8-OHdG [J-1]: sc-
139586, Santa Cruz) was diluted in BD Perm/Wash at 1:250 (stock 
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concentration 100ug/mL, working concentration 400ng/mL), and isotype 
controls were diluted to the same concentration as each primary antibody in 
BD Perm/Wash. For 8-OhdG tests, cells were incubated in secondary 
antibody (Goat Polyclonal Anti-Rabbit IgG H&L [Alexa Fluor® 488], 
Abcam) at 1:2000 (stock concentration 2000ug/mL, working concentration 
1000ng/mL) for an hour at room temperature, before antibody was 
removed, cells were washed twice in BD Perm/Wash, and resuspended in 
300 μL of FACs buffer for analysis. 
 
Cellular fluorescence was measured by flow cytometric analysis, 
carried out on a BD FACS Canto TM II, with BD FACS Diva Software 
Version 8.0.1. Analysis of flow cytometry data was carried out on FlowJo 
10.0.8r1 (FlowJo, LLC, Ashland, OR, USA).  Statistical analysis of FlowJo 
outputs was carried out on Prism 6.0 (GraphPad Software, La Jolla, CA, 
USA).  
Comet Tail Assay/Single Cell Gel Electrophoresis 
Slides used for the comet tail assay (LabServ Superfrost Plus) were 
pre-coated with 1mL of 1% normal melting point agarose (Invitrogen 
UltraPure Agarose) and allowed to air-dry for at least 24 hours prior to the 
start of the assay. Slides were coded with an individual serial number, 
which was randomly assigned to treatment groups and cell lines prior to the 
start of the experiment. Slides were only decoded after analysis. 
 
GL261 cells were harvested and diluted in media to a concentration 
of 1x105 cells/mL, then treated with 6 Grays of ionising radiation, 5mM of 
ascorbate or both agents together. Ascorbate treated cells were pre-treated 
with ascorbate in media for an hour before irradiation. 
 
Cells were added to 1% low melting point agarose at a ratio of 1:10 
(v/v, final cell concentration 1x104 cells/mL), pipetted several times to 
combine, and then released onto a pre-agarose coated slide, in two isolated 
circular areas for each slide. 
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Agarose and cells were allowed to air dry in a laminar flow hood for 
30 minutes at room temperature. 
 
Cells were lysed by placing slides in pre-chilled lysis solution (2.5M 
NaCl, [Sigma Aldrich] 100mM EDTA pH 10 [Invitrogen], 10mM Trizma 
[Sigma], 1% sodium lauryl sarcosinate [Aldrich], and 1% Triton X-100 
[Bio-Rad], pH 10) for 1 hour at 4oC.  
 
Slides were rinsed in 1x TBE, before being placed in a gel 
electrophoresis tank (Bio-Rad) containing 1x TBE and equilibrated for 30 
minutes. The agarose-embedded cells were then electrophoresed 
(Amersham Pharmacia Biotech EPS-301 Electrophoresis Power Supply, 3 
V/cm for 60 minutes) 
 
Slides were stained with 10ug/mL propidium iodide pipetted 
directly onto agarose for 20 minutes at 4oC, rinsed in TBE, and imaged on a 
fluorescent microscope (Olympus BX51 microscope, FluorView software, 
X-Cite Series 120Q mercury lamp, Olympus DP70 camera, TXRED filter). 
Slides were imaged at the longest exposure possible without incurring 
background stain, and exposure was kept identical within each experiment. 
 
Cell nuclei were analysed using Robert Bagall’s ImageJ Comet 
Assay plugin. Briefly, oval selections were used to outline and measure the 
cell nuclei head only, followed by the entire cell nuclei including the comet 
tail. Cell nuclei that overlapped, or were not entirely contained within one 
picture were not analysed. At least 100 cell nuclei per sample per 
experiment were analysed. ImageJ outputs (Table 3) were imported into 
Microsoft Excel for collection by experiment, and averages were imported 
into Prism (GraphPad) V6.0 for analysis. 
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Table 3. Outputs of the ImageJ Comet Tail Plugin 
ImageJ parameter 
output 
Description 
X X coordinate for each centroid 
Y Y coordinate for each centroid 
XM X coordinate for each center of mass 
XY Y coordinate for each center of mass 
IntDen Integrated Density: the product 
of ‘Area’ and ‘Mean Gray Value’ 
RawIntDen Raw Integrated Density: the sum of the values 
of the pixels in the image or selection. 
TailLen Tail Length: the distance from the Centroid of 
the head to the Center of Mass of the tail. 
TailMoment Tail Moment: the length of the tail times the 
integrated density of the tail 
%TailDNA Percentage Tail DNA: the integrated density 
of the tail divided by the integrated density of 
the tail plus the integrated density of the head 
times 100. 
Information from 
(University of North Carolina School of Medicine 2015) 
(Research Services Branch) 
 
Note in this analysis, measurement of the nucleoid ‘tail’ always 
included measurement of the nucleoid ‘head’ as well, thus ‘integrated 
density of the tail’ could be more accurately termed integrated density of 
whole comet (Figure 22). This formula results in a range of 50% (where 
comet head integrated density= whole comet integrated density, i.e. no 
visible tail) to approaching 100% (100% tail DNA is a hypothetical 
maximum whereby no comet tail head would be visible). 
Intracranial Mouse Model 
Experiments using mice were conducted in accordance with the 
New Zealand Animal Welfare Act 1991. All protocols were approved by 
the Victoria University Animal Ethics Committee (Number 2012R18M) 
and done according to their guidelines. 
 
The inbred mouse strain C57BL/6 was originally procured from the 
Animal Resource Centre (Canning Vale, WA). Mice were managed by the 
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Biomedical Research Unit at the Malaghan Institute of Medical Research 
(Wellington, New Zealand). All mice were males 8 to 12 weeks of age. 
 
Approximately 1x106 mouse glioma GL261 cells, stored frozen in 
liquid nitrogen, were thawed, centrifuged at 300g for 5 minutes, washed in 
PBS, and a subset implanted into the brain of 8 to 12 week old (25-30 g) 
male C57BL/6 mice, following the procedure described by Broadley, Hunn 
et al. 2011. 
 
Mice were anesthetized by intraperitoneal (I.P.) injection (UltraFine 
Insulin syringe 1mL, 29G, BD) of xylazine (100 mg/kg) and ketamine (10 
mg/kg) (Phoenix Pharm). Once unconscious, mice were given a sub-
cutaneous injection of buprenorphine analgesic (0.1 mg/kg, Renckitt 
Benckiser Pharmaceuticals), Lacri-Lube (Allergan) was applied across the 
eye and mice were restrained in a stereotaxic frame (Stoelting Apparatus). 
 
The skin and fur of the head were disinfected with an iodine covered 
swab, and an incision was made approximately 1.5 cm along the midline 
with a fresh scalpel (Swann Morton). A burr hole was drilled (Terumo 
Needle, 20G, Neolus) in the skull 1mm posterior to the bregma and 2.3mm 
lateral to the midline (Figure 6). 
 
Cells (1.25x107/mL of PBS) were inoculated via the burr hole using 
a 32-gage needle and Hamilton syringe. The needle was slowly advanced to 
a depth of 4 mm from the brain surface, withdrawn 1 mm, and 2 μL of cell 
suspension delivered over the course of approximately 1 min. The needle 
was left in place for 3-5 min, and then raised slowly. The burr hole was 
sealed with bone wax and the incision sutured (Novafil 18” Surgalloy P-10, 
Covidien) 
 
Following surgery, (immediately following, 24, and 48 hours post-
surgery) animals received sub-cutaneous Carprofen (5 mg/kg, Norbrook 
Laboratories), for treating pain. 
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Animals were weighed at regular intervals and humanely sacrificed 
by CO2 when weight loss occurred (>10% of body weight) or at the 
experimental endpoint; either day 18 for short-term treatment, or day 19 for 
longer-term treatment. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Injection site of GBM cells in the mouse skull. Red X represents site of injection.  
 
Image used with permission from (Paxinos and Watson 1998). This article was published in The Rat Brain in 
Stereotaxic Coordinates, 4th Edition, George Paxinos and Charles Watson, Stereotaxic Reference System, pg. XIV 
to XIV, Copyright Elsevier (1998). 
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Whole Brain Irradiation of Mice 
Mice received a single dose of 10 Gy to the brain on day 18 or 19 
after surgery. The irradiator uses a Cesium-137 source (length 27 cm, 
diameter 1.7 cm; nominal activity 48 TBq). 
 
Mice were anesthetized with an intraperitoneal (I.P.) injection of 
xylazine (100 mg/kg) and ketamine (10 mg/kg). Once unconscious, 
Lacrilube was spread across the cornea and mice were placed upright in a 
50mL Falcon tube with a hole at the tip for breathing, and tissue paper at 
the base to prevent movement. The tube was placed inside a 2 cm thick 
custom-built lead shield, such that only the mouse’s head above the ears is 
exposed to radiation. The shielding was placed in the centre of the steel 
cylinder (Figure 7). 
Tumour Harvest 
Mice were culled with a CO2 chamber, then perfused with 10mL of 
PBS and 10mL of 10% neutral buffered formalin. Tumour-containing 
brains were transferred into a 15mL Falcon tube that contained 3mL of 10% 
neutral buffered formalin and fixed overnight (approximately 18 hours) at 
4oC before being transferred into 4mL of 70% molecular grade ethanol and 
stored at 4oC until processing. Total time between tumour harvest and 
processing was less than 2 weeks. 
Tissue Processing and Immunofluorescence Assay 
Brains were bisected by hemisphere and dehydrated through a series 
of ethanol concentrations, xylol and wax (Table 4) with an automated tissue 
processor (Leica TP1020, Leica Biosystems). 
 
 64 
 
Table 4. Automated Tissue Processor Program 
Reagent Time 
70% Ethanol 2 hours 
80% Ethanol 1 hour 30 minutes 
95% Ethanol 1 hour 
95% Ethanol 1 hour 
Absolute Ethanol 1 hour 30 minutes 
Absolute Ethanol 1 hour 15 minutes 
Absolute Ethanol 1 hour 15 minutes 
1:1 Absolute Ethanol/Xylol 1 hour 30 minutes 
Xylol 1 hour 
Xylol 1 hour 
Wax 1 hour 30 minutes 
Wax (with vacuum) 2 hours 
 
Hemispheres were set in paraffin wax with a paraffin embedding 
machine (Leica EG1160, Leica Biosystems); 5 micron slices were sectioned 
from the block with a microtome (Leica RM2235, Leica Biosystems), 
transferred via a waterbath (Leica HI1210, Leica Biosystems), and dried on 
SuperFrost slides. 
 
Slides were stored at 4oC until staining. 
 
Slides were rehydrated in a series of xylene and ethanol steps (Table 
5). 
 
Table 5. Immunofluorescence Protocol 
Reagent Time 
Xylene 2x 10 minutes 
Absolute Ethanol 4x 2 minutes 
90% Ethanol 4x 2 minutes 
70% Ethanol 4x 2 minutes 
ddH2O 4x 2 minutes 
10mM Sodium Citrate buffer, pH 6, boiling 10 minutes at 95oC 
+ 20 minute cooling 
TBST rinse 3x 5 minutes 
5% BSA (in TBST) block 1 hour at room 
temp. 
Primary antibody in 1% BSA (in TBST) 1 hour at room 
temp. 
TBST rinse 3x 5 minutes 
DAPI Anti-fade mounting media, coverslip  
 65 
 
Slides were imaged on a fluorescent microscope (Olympus BX51 
microscope, FluorView software, X-Cite Series 120Q mercury lamp, 
Olympus DP70 camera, DAPI filter for nuclear imaging, FITC filter for 
Alexa Fluor 488 tagged H2AX and 8-OH, and Cy5 filter for Alexa Fluor 
647 tagged H2AX) and analysed with ImageJ. The entirety of one brain 
hemisphere slice in each sample mouse, including regions of tumour, was 
observed in each immunofluorescent experiment. 
Statistical Analysis 
Graphed values are averages plus or minus statistical error of the 
mean (SEM). The statistical significance of differences between treatments 
was determined by paired (mice weights) or unpaired (flow cytometry and 
comet tail assays) two-tailed Student t tests; a p value less than 0.05 was 
considered statistically significant. 
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Figure 7. A graphical representation of whole brain mouse irradiation 
From (Grasso, Fabre et al. 2014) 
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 Results 
The ultimate aim of this project was to determine whether ascorbate 
has any pro-oxidant activity in a brain tumour model. Pro-oxidant activity 
would lead to radio-sensitisation and determine the suitability of ascorbate 
as a radiotherapy adjuvant in GBM cancer therapy. 
 Analysis of DNA Damage In Vitro 
The first objective of the project was to confirm whether ascorbate 
had radiosensitisation activity in vitro on GL261 cells, a murine model of 
GBM and the same cells that would be used in vivo. To this end, flow 
cytometry and the single cell gel electrophoresis assay were used to 
determine whether ascorbate induced oxidative damage and double 
stranded DNA breaks in GL261 cells. 
Flow Cytometry 
Cells were plated, and at 40% confluence were treated with either 6 
Gy of irradiation, 5 mM of ascorbate for 60 min, 500 μM of hydrogen 
peroxide for the same length of time, or both ascorbate and irradiation. For 
cells that received both ascorbate and irradiation, ascorbate was given as a 
pre-treatment 60 minutes prior to irradiation. After irradiation, cells were 
harvested before being processed for analysis using an antibody to either 
H2AX or 8-OHdG. 
 
Figure 8 describes the flow cytometric analysis including gating 
procedures used throughout.  Each experiment was grouped by cell line and 
concentration of antibody. Within each group, cells in the control sample 
was gated on FSC (forward scatter) and SSC (side scatter) to eliminate 
debris, and the gate was copied to every other sample within that group. 
Single cell events were identified using forward scatter area (FSC-A) and 
forward scatter height (FSC-H), and gated to eliminate double cells 
(doublets). Finally, a quadrant gate was inserted to the right of the main 
population of control cells in order to measure the proportion of cells that 
were more fluorescent than the control population.  
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Figure 8. Example representative analysis of flow cytometry cell data 
Specific analysis displayed is of unstained T98G cells. Cells were plated, treated, and harvested 
before being stained with antibody for a specific marker. Fluorescence was measured by BD FACS 
Canto TM II, with BD FACS Diva Software Version 8.0.1. A. Data was imported into FlowJo 
10.0.8r1 and grouped by cell line, fluorophore marker, and antibody concentration. B. Cells were 
separated from debris by gating on side scatter light area (SSC-A) and forward scatter light area 
(FSC-A). C. Single cells were separated from doublet cells by gating on forward scatter light height 
(FSC-H) and FSC-A. D. Cells were graphed on SSC-A and the fluorophore marking the protein of 
interest (in this case Alexa Fluor 488-A indicating H2AX ). Median fluorescence intensity was 
determined by the median fluorophore value on the x axis. Percent positive was determined by the 
percentage of cells to the right of a gate inserted relative to control cells. 
 69 
Figure 9 displays a typical graphical output for one experiment. Unstained 
negative control and isotype control cell populations are nearly entirely, or 
entirely to the left of the final quadrant gate, with no positive fluorescence. 
Control cells serve as a marker of the basal level of DNA damage, and 
treated cell populations are shifted to the right relative to the control 
population, indicating an increase in fluorescence, thus an increase in the 
proportion of cells positive for the marker investigated. This particular 
experiment displays H2AX fluorescence in response to ascorbate, 
irradiation, and combination treatments. The combination of irradiation and 
ascorbate has more cells with bright H2AX staining (shifted to the right 
more strongly) than either treatment alone.  
H2AX 
H2AX is a modified histone marker of DNA damage, an instigator 
of the DNA damage response, and often interpreted as a marker of DSBs. 
DSBs are an important indicator because they are considered to be the most 
damaging DNA alteration, and most likely to cause cell death, because they 
are the most difficult to repair correctly. Even if it does not indicate only 
DSBs (see Takahashi and Ohnishi 2005), DNA damage in general is also an 
indicator of the cell’s likelihood of death, for an accumulation of any DNA 
damage over a threshold will lead to cell death. 
 
In this investigation, intensity of H2AX was used in vitro as one 
indication of the type of damage that can be caused by ascorbate and 
irradiation, in order to corroborate similar data from human cell lines 
(Castro, McConnell et al. 2014).  
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Figure 9. Representative example of H2AX analysis in GL261 cells in response to treatment 
Specific analysis is of H2AX staining of GL261 cells in response to various treatments. Plotted in 
FlowJo 10.0.8r1. Left to right, top row: Control, Unstained negative control, Isotype negative 
control. Left to right, second row: Ascorbate treated, Irradiation treated, both Ascorbate and 
Irradiation treated. Cells were stained, measured and analysed as described in Figure 8. Cells were 
plotted by SSC-A and fluorophore indicating protein marker of interest, and gated relative to 
untreated control cells. The number in the bottom right hand side of each graph indicates the 
percentage of total cells where antibody staining exceeded the gate. The gate was inserted according 
to the position of control untreated cells and applied to all other treatments. 
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Figure 10 shows H2AX levels in GL261 cells in response to 
irradiation, ascorbate, and both treatments in combination. Each sample was 
gated as described in Figure 8. The effect of each treatment on H2AX was 
calculated as percent positive cells, meaning the percentage of cells to the 
right of the gate as shown in Figure 9. Each treated cell was normalised to 
control, untreated cells then calculated as a fold change. The data show that 
while ascorbate increased the proportion of H2AX positive cells nearly 3-
fold, irradiation increased it nearly 3.1 fold, and both irradiation and 
ascorbate together caused H2AX percentage positive staining to increase 
nearly 4-fold. The increase in H2AX with both treatments is thus less than 
additive. 
 
Counting the number of positive cells is not necessarily informative. 
While the number of cells positive for a marker may not change, the 
amount of signal per cell can change, and changes in the level of signal in a 
cell is equally biologically relevant. The signal per cell is directly 
measured, and the effect on a population of cells calculated by analysis of 
the Median Fluorescence Intensity (MFI) of that population, along a 
fluorescence axis.   
 
The MFI for H2AX in GL261 cells in response to irradiation, 
ascorbate, and both treatments in combination is shown in Figure 11. 
Irradiation increases the H2AX staining per cell, compared to control, 5.8-
fold.  Ascorbate increases that metric only 3.2-fold, less than irradiation, 
and combination treatment increases H2AX more than either treatment 
alone, 12.2-fold. 
 
The effect of combined treatment was greater in the amount of 
H2AX per cell (MFI) than in the number of H2AX positive cells, and 
results in an apparently synergistic interaction between ascorbate and 
irradiation in this case. 
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Figure 10. Flow cytometry derived percent positive H2AX staining in GL261 cells 
Flow cytometry derived percent positive H2AX staining (fold change + Standard Error of the Mean 
[SEM]) by treatment group for the GL261 cell line. Graph includes data from 8 independent 
experiments, and each treatment group has a sample size of between 5 and 8 experiments. All three 
treatment groups were statistically significantly greater than control (P values: Gy 0.0046, AA 
0.0158, AA+Gy 0.0008). Graph and statistics produced with Prism V6.0.  
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Figure 11. Flow cytometry derived median fluorescence intensity H2AX staining in GL261 
cells 
Flow cytometry derived median fluorescence intensity H2AX staining (fold change + Standard 
Error of the Mean [SEM]) by treatment group for the GL261 cell line. Graph includes data from 8 
independent experiments, and each treatment group has a sample size of between 5 and 8 
experiments. Irradiation and combination treatment groups were statistically significantly greater 
than control (P values: Gy 0.0156, AA 0.1201, AA+Gy 0.0267). Graph and statistics produced with 
Prism V6.0
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These experiments were repeated with a human GBM cell line, to 
determine how well Gl261 represents human glioma cells. The T98G cell 
line is an immortalised human GBM-derived cell line commonly used in 
brain cancer research. It is adherent like GL261, and in our laboratory is the 
most ascorbate resistant GBM cell line (Castro, McConnell et al. 2014).  
 
Figure 12 presents the effect of ascorbate, irradiation and 
combination treatments on H2AX staining in T98G cells displayed as fold 
change percent positive. With this cell line, irradiation only caused the 
greatest H2AX increase, nearly 4-fold in comparison with control, while 
ascorbate only caused a minimal increase, around 1-fold. This corroborates 
a previous paper that found T98Gs had a much greater antioxidant capacity 
than other GBM cell lines (Castro, McConnell et al. 2014). Interestingly in 
this case, combination treatment seemed to cause less H2AX positive 
staining than irradiation only, with just over 2.5-fold more H2AX positive 
staining. 
 
In Figure 13, T98G, like GL261, is assessed with MFI to 
complement percent positive display. MFI shows ascorbate caused a 
similar, minimal fold change increase in H2AX signal of T98G cells 
compared to control, and irradiation only resulted in about 5-fold 
amplification, comparable to the percent positive data. Most interestingly, 
in comparison with the previous graph of percent positive cells, 
combination treatments were additive, with a greater H2AX positive 
signal compared with either irradiation or ascorbate alone.  
 
This data shows that irradiation alone caused a greater percentage of 
the total cell population to fluoresce positive for H2AX, and ascorbate 
appeared to decrease this proportion in combined treatments. Yet, looking 
at the combination fluorescence with MFI, both treatments caused more 
fluorescence per individual cell compared with either ascorbate or 
irradiation alone. 
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Figure 12. Flow cytometry derived percent positive H2AX staining in T98G cells 
Flow cytometry derived percent positive H2AX staining (fold change + Standard Error of the Mean 
[SEM]) by treatment group for the T98G cell line. Graph includes data from 7 independent 
experiments, and each treatment group has a sample size of between 5 and 7 experiments. Irradiation 
and combination treatment groups were statistically significantly greater than control (P values: Gy 
0.0048, AA 0.7380, AA+Gy 0.0232). Graph and statistics produced with Prism V6.0. 
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Figure 13. Flow cytometry derived median fluorescence intensity H2AX staining in T98G 
cells 
Flow cytometry derived median fluorescence intensity H2AX staining (fold change + Standard 
Error of the Mean [SEM]) by treatment group for the T98G cell line. Graph includes data from 7 
independent experiments, and each treatment group has a sample size of between 5 and 7 
experiments. Irradiation was statistically significantly greater than control (P values: Gy 0.0139, AA 
0.9662, AA+Gy 0.1527). Graph and statistics produced with Prism V6.0. 
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1003 is another alternative GBM cell type used in this investigation. 
It differs from GL261 and T98G in that it is a human primary GBM cell 
developed from material from patients undergoing debulking surgery, 
rather than an immortalised cell line. Because it has undergone less 
passaging, and presumably genetic change, since the original in situ 
tumour, 1003 might be considered a closer representation of GBM in its 
native state. Although each individual tumour will have its own particular 
tumorigenic alterations (see ‘Glioblastoma Multiforme’). 
 
Figure 14 displays results from the same experiment undertaken on 
the cell lines, as described in Figures 10-13, carried out on 1003 cells. 1003 
cells followed a similar trend as the cell lines. Irradiation only gave rise to 
an approximately 2.5 fold increase in H2AX positive fluorescence, 
ascorbate caused a similar but more variable amplification in the marker, 
and combination treatment showed the greatest increase in an less than 
additive manner. 
 
Finally, 1003 is also laid out with MFI analysis in Figure 15. In a 
similar fashion to the previous two cell types, MFI processed data from 
1003 cells enhanced variation between treatment groups compared to 
percent positive analysis. Ascorbate treated cells fluoresced only slightly 
more than control cells, while irradiation caused many fold more H2AX 
signal per cell, an average of 7 times more fluorescence. Combination 
treatment resulted in the most H2AX fluorescence per cell in an additive 
way, with a nearly 8-fold mean increase, although this was not statistically 
significantly more than irradiation alone. 
 
In conclusion, 3 GBM cell types with vastly different origins; a 
murine GBM model, an immortalised human GBM cell line, and a human 
primary cell derived directly from a patient, have been treated with the 
same doses of ascorbate and irradiation in the same experiments, and 
H2AX fluorescence was measured with flow cytometry. Although each 
cell type has inevitable variation, overall trends are remarkably consistent. 
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Specifically, this overall trend is that both ascorbate and irradiation increase 
the fluorescence of H2AX, irradiation more so than ascorbate, while cells 
that are treated with both present with H2AX stain higher than either 
treatment alone. 
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Figure 14. Flow cytometry derived percent positive H2AX staining in 1003 cells 
Flow cytometry derived percent positive H2AX staining (fold change + Standard Error of the Mean 
[SEM]) by treatment group for the 1003 cell line. Graph includes data from 3 independent 
experiments, and all treatment groups have a sample size of 3 experiments. Irradiation and 
combination treatment groups were statistically significantly greater than control (P values: Gy 
0.0032, AA 0.3174, AA+Gy 0.0057). Graph and statistics produced with Prism V6.0. 
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Figure 15. Flow cytometry derived median fluorescence intensity H2AX staining in 1003 cells 
Flow cytometry derived median fluorescence intensity H2AX staining (fold change + Standard 
Error of the Mean [SEM]) by treatment group for the 1003 cell line. Graph includes data from 3 
independent experiments, and all treatment groups have a sample size of 3 experiments. No treatment 
groups were statistically significantly greater than control (P values: Gy 0.3382, AA 0.6105, AA+Gy 
0.3257).  Graph and statistics produced with Prism V6.0. 
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8-hydroxy-2-deoxyguanosine 
8-hydroxy-2-deoxyguanosine (8-OHdG), like H2AX, is an 
indicator of DNA damage. It is a particular hydroxylation modification of 
the guanosine DNA nucleoside that forms in response to oxidative stress. In 
this investigation it was measured with flow cytometry alongside H2AX, 
in order to compare the specific types of damage caused by ascorbate and 
irradiation individually and in combination. As an additional treatment 
group for this indicator, 500µM of hydrogen peroxide was included as a 
positive control, since hydrogen peroxide’s mechanism of DNA damage is 
oxidative stress from reactive oxygen species (see ‘DNA Damaging Effects 
of Ascorbate’). Data for 8-OHdG were generated and presented in the same 
way as the H2AX indicator, with the only difference being the use of a 
secondary antibody and the additional hydrogen peroxide group. 
 
Figure 16 is the percent positive presentation fold change of 8-
OHdG fluorescence in response to the various treatment groups for the 
GL261 cell line. For this cell line, H2O2 response was surprisingly low, only 
around 1.5-fold greater than control untreated cells. Irradiation alone and 
combination treatments were approximately similar, reaching to around 2-
fold higher than control, while ascorbate only caused 3.5-fold greater 8-
OHdG signal. 
 
The high ascorbate result is not greatly surprising, as the ascorbate 
DNA damaging effect will be caused by prooxidant species that cause the 
particular DNA damage 8-OHdG. However, the lower 8-OHdG result in 
response to combination treatments is dissimilar to that found with H2AX. 
This interesting outcome appears to show irradiation decreased the number 
of cells with 8-OHdG due to ascorbate. Another interesting point to note is 
the difference between ascorbate and hydrogen peroxide. Hypothetically, 5 
mM ascorbate should produce a similar degree of damage as 50 μM 
hydrogen peroxide (Castro, McConnell et al. 2014), however this 
calibration was calculated with intracellular ROS load, and thus may not be 
directly applicable to the different marker. 
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As an example of the need to analyse data from all perspectives, 
Figure 17 displays the same experiments as Figure 16, but showing median 
level of 8-OHdG per cell, instead of percent positive cells. In this case the 
trend is quite different. Although combination treatment has a smaller 
proportion of 8-OHdG positive cells than ascorbate alone, it appears that 
these cells have an overall greater fluorescence when viewed this way. 
Compared with irradiation only, combination treatment causes about the 
same proportion of cells to show DNA damage, but judging by overall MFI, 
cells that are damaged already become more damaged by with both 
treatments. Therefore, in this case combination treatment causes cells that 
are already damaged to become more so. 
 
Another interesting aspect is the relatively higher 8-OHdG signal 
per cell in response to hydrogen peroxide in MFI graphs as opposed to 
percent positive of the population. Instead of possessing only half the 8-
OHdG as ascorbate in percent positive display, indicating a less widespread 
induction of DNA damage, MFI shows hydrogen peroxide causing an even 
more substantial response in the subset of cells that are affected. 
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Figure 16. Flow cytometry derived percent positive 8-hydroxy-2-deoxyguanosine staining in 
GL261 cells 
Flow cytometry derived percent positive 8-hydroxy-2-deoxyguanosine staining (fold change + 
Standard Error of the Mean [SEM]) by treatment group for the GL261 cell line. Graph includes data 
from 10 independent experiments, and each treatment group has a sample size of between 4 and 10 
experiments. Ascorbate and hydrogen peroxide treatment groups were statistically significantly 
greater than control (P values: Gy 0.1904, AA 0.0117, AA+Gy 0.2160, H2O2 < 0.0001). Graph and 
statistics produced with Prism V6.0. 
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Figure 17. Flow cytometry derived median fluorescence intensity 8-hydroxy-2-deoxyguanosine 
staining in GL261 cells 
Flow cytometry derived median fluorescence intensity 8-hydroxy-2-deoxyguanosine staining (fold 
change + Standard Error of the Mean [SEM]) by treatment group for the GL261 cell line. Graph 
includes data from 10 independent experiments, and each treatment group has a sample size of 
between 4 and 10 experiments. Ascorbate and hydrogen peroxide treatment groups were statistically 
significantly greater than control (P values: Gy 0.3119, AA 0.0167, AA+Gy 0.1723, H2O2 0.312). 
Graph and statistics produced with Prism V6.0. 
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Figure 18. Flow cytometry derived percent positive 8-hydroxy-2-deoxyguanosine staining in 
T98G cells 
Flow cytometry derived percent positive 8-hydroxy-2-deoxyguanosine staining (fold change + 
Standard Error of the Mean [SEM]) by treatment group for the T98G cell line. Graph includes data 
from 5 independent experiments, and each treatment group has a sample size of between 3 and 5 
experiments. Irradiation and ascorbate treatment groups were statistically significantly greater than 
control (P values: Gy 0.0021, AA 0.0006, AA+Gy 0.0515, H2O2 0.1551). Graph and statistics 
produced with Prism V6.0.
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Figure 19. Flow cytometry derived median fluorescence intensity 8-hydroxy-2-deoxyguanosine 
staining in T98G cells 
Flow cytometry derived median fluorescence intensity 8-hydroxy-2-deoxyguanosine staining (fold 
change + Standard Error of the Mean [SEM]) by treatment group for the T98G cell line. Graph 
includes data from 5 independent experiments, and each treatment group has a sample size of 
between 3 and 5 experiments. Irradiation and ascorbate treatment groups were statistically 
significantly greater than control (P values: Gy 0.0161, AA 0.0234, AA+Gy 0.0710, H2O2 0.9103). 
Graph and statistics produced with Prism V6.0. 
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Figure 18 set outs the of number 8-OHdG positive cells in response 
to treatment in the T98G cell line. In this particular case, treatments are 
remarkably alike in their fluorescence as irradiation, ascorbate, and 
combination treatments all increase 8-OHdG around 5-fold over control 
cells. Hydrogen peroxide is the anomaly, increasing the proportion of cells 
with 8-OHdG damage only 3-fold. 
 
In Figure 19, the median level of 8-OHdG in each population is 
graphed for T98G cells, and again shows similar effects to that seen with 
percent positive. With MFI scoring, irradiation only treatment has higher 8-
OHdG than all other, including combination treatments, compared to 
percent positive. All treatments except hydrogen peroxide increase 8-OHdG 
per cell approximately 2-fold. Similar to percent positive, hydrogen 
peroxide provokes the least increase in 8-OHdG per cell, at only 1.1-fold 
greater than control. 
 
Finally, 8-OHdG response to treatment was investigated in 1003 
cells (Figure 20). This resulted in quite a different effect from the other two 
cells. For instance, irradiation alone caused a large effect, approximately 
7.5-fold increase over control cells. Hydrogen peroxide caused a slightly 
larger increase than irradiation only. The high level of increase in the 
proportion of 8-OHdG cells with hydrogen peroxide indicates perhaps that 
1003s are not quite as resilient to hydrogen peroxide mediated-oxidative 
stress as the other two cell lines that produced a lower 8-OHdG signal. Also 
dissimilar to GL261 and T98G, 1003 8-OHdG staining showed that 
ascorbate and combination treatments have much lower effect than 
irradiation alone, around 2 and 5-fold respectively. This is unexpected, as 
ascorbate is thought to mediate DNA damage by reactive oxygen species, 
which would be predicted to cause a high level of oxidative damage and so 
8-OHdG modifications. Yet, relative to other cell lines, ascorbate only 
treatment for 8-OHdG in 1003 cells has a comparable fold change response, 
at 2.3-fold, to GL261 percent positive (Figure 10). Combination treatment 
fold change, around 4.7-fold is similar to that seen in T98G 8-OHdG 
combination treatment. 
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Figure 21 presents MFI analysis for the same data. The overall trend 
is much the same, only with irradiation treatment causing a greater increase 
in 8-OHdG signal than hydrogen peroxide treatment. Again, ascorbate only 
barely increased the amount of 8-OHdG in cells, while the combination 
treatment increased it not quite 2-fold. 
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Figure 20. Flow cytometry derived percent positive 8-hydroxy-2-deoxyguanosine staining in 
1003 cells 
Flow cytometry derived percent positive 8-hydroxy-2-deoxyguanosine staining (fold change + 
Standard Error of the Mean [SEM]) by treatment group for the 1003 cell line. Graph includes data 
from 12 independent experiments, and each treatment group has a sample size of between 7 and 12 
experiments. All treatment groups were statistically significantly greater than control (P values: Gy 
0.0034, AA 0.0076, AA+Gy 0.0364, H2O2 0.167).  Graph and statistics produced with Prism V6.0. 
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Figure 21. Flow cytometry derived median fluorescence intensity 8-hydroxy-2-deoxyguanosine 
staining in 1003 cells 
Flow cytometry derived median fluorescence intensity 8-hydroxy-2-deoxyguanosine staining (fold 
change + Standard Error of the Mean [SEM]) by treatment group for the 1003 cell line. Graph 
includes data from 12 independent experiments, and each treatment group has a sample size of 
between 7 and 12 experiments. All treatment groups were statistically significantly greater than 
control (P values: Gy 0.423, AA 0.0007, AA+Gy 0.0216, H2O2 0.0002). Graph and statistics 
produced with Prism V6.0. 
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Single Cell Gel Electrophoresis/Comet Tail Assay 
The single cell gel electrophoresis assay, also known as the comet 
tail assay, was established as an additional assay to investigate ascorbate’s 
induction of DSBs, and so confirm ascorbate’s radiosensitising role in vitro, 
the first objective of the project.  
Cells were harvested and treated with the same dose of ascorbate or 
irradiation as in the flow cytometry assay, before being embedded in low 
melting point agarose, lysed, and electrophoresed. The DNA was stained 
with PI and imaged to assess relative DSB DNA damage. This particular 
variant of the comet tail assay is designed to detect DSBs only, as it is 
carried out under neutral conditions and so should not incorporate other 
types of damages, such as single stranded breaks (SSBs). 
Analysis 
As described in ‘Methods’, cell nuclei/ ‘comets’ were analysed with 
a ImageJ plugin designed for analysis of the comet tail assay. Figure 22 
displays an example analysis of one typical cell nuclei and the graphical 
output from ImageJ. 
 
Figure 23 is an example of cell nuclei response to treatment. This 
figure shows typical comet tails produced from either untreated control 
cells (on the left) compared with cells that were treated with 80 Gy of 
irradiation. As can be seen on the left, even untreated cells have a basal 
level of DSBs, represented by small tails emanating from some cell nuclei. 
Cells treated with 80 Gy, the highest dose used in this investigation, 
produce comet tails that are severely fragmented, due to the large 
proportion of DSBs caused by this high dose.  
 
Because this assay had not been established in the lab, two 
experiments were carried out in order to optimise and validate the process; 
an ascorbate time course and irradiation dose response. 
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Figure 22. Graphical representative analysis of comet tails using the ImageJ comet tail plugin 
A. An oval is drawn around the comet tail head. B. The oval is extended to encircle the comet including the 
tail. C. The measurements are confirmed and a numbered label is added to the comet image. D. Data is 
displayed in an ImageJ window before export to Excel.  
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Figure 23. Example display of typical comet nuclei in response to either no treatment (L) or 80 
Gy of irradiation (R) 
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Ascorbate Time Course 
From H2AX experiments, it was expected that ascorbate would 
cause an increase in DSBs, or at least general DNA damage. An ascorbate 
time course was an opportunity to confirm ascorbate was causing DSBs in 
particular and determine whether this increased over time, as well as 
investigate a general rate of repair. 
 
Figure 24 exhibits the results of this ascorbate time course in GL261 
cells, using the comet tail assay parameter that was found to be the most 
reproducible, tail length. The aim of the experiment was to try and pinpoint 
from what time ascorbate begins to cause DSB damage, what is the rate of 
increase in DSBs over time in response to ascorbate, and how long is 
required without the presence of ascorbate to repair DSBs created. 
 
To the left of the partition are time points for how long GL261s 
were exposed to ascorbate in media, between 15 minutes and 3 hours. Note 
each of these times describes the length cells were incubated in ascorbate at 
the 5 mM concentration before being diluted in agarose. Thus the total 
amount of time each group was exposed to any ascorbate was the time point 
label plus 30 minutes required to allow drying of agarose before lysis. 
Ascorbate causes a clear increase in DSBs over time, such that even at 15 
minutes, tail length is nearly 4-fold longer than control untreated cells, and 
at the longest time point, 3-hour treatment, ascorbate resulted in a 7-fold 
increase in tail length. However, these DSBs are fairly rapidly repaired. 
 
To the right of the partition are two time points that outline the swift 
repair of DSBs by GL261s, at least for cells that do not die outright. For 
these time points, cells were treated for one hour with ascorbate, before 
being allowed to recover in ascorbate free media for the indicated time, 
minus treatment time. Either 7 or 23 hours post ascorbate treatment, cells 
were harvested and processed in the same manner as other time points. 
Both 8 hours and 24 hours after initialisation of ascorbate treatment, tail 
length fold change was approaching 1 relative to control, indicating nearly 
all DSBs had been repaired before this time. However, because media was 
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aspirated during the harvesting process, cells that had died and were in 
suspension would not have been included. 
 
Figure 25 represents data from the same ascorbate time course, yet 
with another comet tail parameter, tail moment. Tail Moment is the length 
of the tail times the integrated density of the tail (see ‘Methods: Comet tail 
assay/Single cell gel electrophoresis’), thus is a measure that combines how 
long the comet tail is, as well as the extent of DNA that has been 
electrophoresed into the tail. Tail moment analysis of the data gives a not as 
clear trend as tail length. In the treatment time points, 15 minutes is low, 
while each other time point appears roughly similar, apart from the clear 
anomaly of a large tail moment average in the 1.5-hour time point. As with 
tail length, tail moment displays almost complete repair of DSBs within 7 
hours of recovery time. 
 
The percentage of the DNA in the tail is another parameter output 
produced by the comet tail plugin. Figure 26 displays the results of the 
ascorbate time course percent tail DNA measures. Interestingly, percentage 
tail DNA varied only very little in all the comet tail assay experiments 
undertaken for this investigation. This may be related to the particulars of 
the comet tail assay plugin, which, for this parameter, limits the amount of 
variation possible between each treatment group by expressing values as 
percentage values between 50 and 100. 
 
In this analysis, plugin measurement allowed either the comet head 
only, or the entire comet (see Figure 22). Therefore, the output, although 
correlated with the true percentage of DNA in the tail, was not strictly a 
measure of percent tail DNA. 
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Figure 24. Single cell gel electrophoresis ascorbate time course tail lengths 
Single cell gel electrophoresis ascorbate time course tail lengths (fold change + Standard Error of the 
Mean [SEM]) with GL261 cells. In the treatment groups to the left of the dotted line, cells were 
exposed to 5 mM of ascorbate for the time indicated before combination with agarose and 
application onto pre-agarose coated slides. Cell-containing agarose was allowed to dry for 30 
minutes on slides before lysis. In the treatment groups to the right of the dotted line, cells were 
allowed to recover in un-ascorbate exposed media. Cells were exposed to ascorbate for a set 30 
minutes before incubation in fresh media. Cells were harvested, combined with agarose and lysed at 
the given time post initiation of treatment. Graph contains data from 11 independent experiments, 
and each time point has a sample size of between 1 and 7 experiments. All time points except for 
Ascorbate 15m, 1hr + 8hr recovery, and 1hr + 24hr recovery were statistically significantly higher 
than control (P values: 15m 0.0552, 30m 0.0361, 1hr 0.0338, 1.5hr 0.0029, 3hr 0.0004, 1hr + 8hr 
recovery and 1hr + 24 hr recovery n/a. Graph and statistics produced with Prism V6.0. 
.
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Figure 25. Single cell gel electrophoresis ascorbate time course tail moments 
Single cell gel electrophoresis ascorbate time course tail moments (fold change + Standard Error of 
the Mean [SEM]) with GL261 cells. Cells were analysed as described in Figure 24. Ascorbate 15m, 
1.5hr, and 3hr were statistically significantly higher than control (P values: 15m 0.0282, 30m 0.1331, 
1hr 0.0550, 1.5hr 0.0095, 3hr 0.0140, 1hr + 8hr recovery and 1hr + 24 hr recovery n/a. Graph and 
statistics produced with Prism V6.0.  
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Figure 26. Single cell gel electrophoresis ascorbate time course percent tail DNA 
Single cell gel electrophoresis ascorbate time course tail moments (fold change + Standard Error of 
the Mean [SEM]) with GL261 cells. Cells were analysed as described in Figure 24. Ascorbate 30m, 
1hr, and 1.5hr were statistically significantly higher than control (P values: 15m 0.0771, 30m 0.0118, 
1hr 0.0103, 1.5hr 0.0005, 3hr 0.2151, 1hr + 8hr recovery and 1hr + 24 hr recovery n/a. Graph and 
statistics produced with Prism V6.0. 
 
 99 
 
Whereas true percent tail DNA is calculated as described in the methods 
section: 
 
% Tail DNA = Int. Density of Tail 
 Int. Density of Tail + Int. Density of Head 
 
The comet tail plugin calculated a related but not identical: 
 
% Tail DNA= Int. Density of Head - Int. Density Total 
Int. Density of Head + Int. Density Total 
 
As mentioned in methods, this formula results in a range of 50% to 
near 100%, although most commonly comets were measured as ~50-60% 
tail DNA. 
Irradiation Dose Response  
The second optimisation and validation experiment was a radiation 
dose response. Doses were chosen starting from the standard 6 Gy used in 
flow cytometry experiments, up until the large dose of 80 Gy. 
 
Figure 27 sets out the fold change increase in tail length caused by 
the various doses of irradiation. It can be seen that even the lowest dose of 6 
Gy caused an increase in comet tail length, around 3-fold longer on average 
than control untreated cells. The increasing doses increased the tail length 
in a reproducible and predictable manner, and the largest irradiation dose, 
80 Gy, caused a fold change increase of approximately 7-fold greater than 
control. This supports increasing doses of irradiation causing a dose-
dependent increase in the number of DSBs. 
 
Figure 28 represents the tail moment from the same experiments. 
Tail moment is the integrated density of the comet tail times the length of 
the tail. For the lower doses, it broadly follows the trend of increasing 
DSBs in response to increasing amounts of irradiation, although at higher 
doses the tail moment reaches a plateau, and even decreases. There are at 
least two explanations for this: either tail moment’s inherent higher 
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variability means that the final two doses, which were only analysed in one 
and two experiments respectively, need more replicates to increase and 
continue the trend; or, at higher doses of irradiation the integrated tail 
density does reach a plateau, and, because tail moment incorporates tail 
density into that parameter, tail moment plateaus also.  
 
Percentage tail DNA for the irradiation dose response experiment is 
presented in Figure 29. In a similar way to the percent tail DNA in the 
ascorbate time course (Figure 26), this measure does not vary enough to be 
interpretable. 
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Figure 27. Single cell gel electrophoresis irradiation dose response tail lengths 
Single cell gel electrophoresis irradiation dose response tail lengths (fold change + Standard Error of 
the Mean [SEM]) with GL261 cells. Cells were exposed to a given dose of irradiation before 
combination with agarose and application onto pre-agarose coated slides. Cell-containing agarose 
was allowed to dry for 30 minutes on slides before lysis. Graph contains data from 10 independent 
experiments, and each time point has a sample size of between 1 and 10 experiments. All irradiation 
doses except 40 Gy were statistically significantly higher than control (P values: 6 Gy 0.0081, 12 Gy 
0.0006, 20 Gy 0.0033, 40 Gy n/a, and 80 Gy < 0.0001. Graph and statistics produced with Prism 
V6.0. 
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Figure 28. Single cell gel electrophoresis irradiation dose response tail moments. 
Single cell gel electrophoresis irradiation dose response tail moments (fold change + Standard Error 
of the Mean [SEM]) with GL261 cells. Cells were treated as described in Figure 27. Graph contains 
data from 10 independent experiments, and each time point has a sample size of between 1 and 10 
experiments. All irradiation doses except 40 Gy were statistically significantly higher than control (P 
values: 6 Gy 0.0139, 12 Gy 0.0028, 20 Gy 0.0081, 40 Gy n/a, and 80 Gy < 0.0001. Graph and 
statistics produced with Prism V6.0. 
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Figure 29. Single cell gel electrophoresis irradiation dose response percent tail DNA 
Single cell gel electrophoresis irradiation dose response percent tail DNA (fold change + Standard 
Error of the Mean [SEM]) with GL261 cells. Cells were treated as described in Figure 27. Graph 
contains data from 10 independent experiments, and each time point has a sample size of between 1 
and 10 experiments. All irradiation doses except 40 Gy were statistically significantly higher than 
control (P values: 6 Gy 0.0003, 12 Gy 0.3796, 20 Gy 0.0207, 40 Gy n/a, and 80 Gy 0.0016. Graph 
and statistics produced with Prism V6.0. 
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Combination Treatments 
The single cell gel electrophoresis, or comet tail assay, was also 
used to assess the effect of ascorbate on irradiation treatment in vitro. In the 
same manner as the flow cytometry experiment, cells were treated with 6 
Gy irradiation, 5 mM ascorbate and both treatments in combination. For 
this assay, an additional control was included, treatment of cells with 
ascorbate in PBS instead of media. This negative control was designed to 
assess the importance of transition metals present in the media, particularly 
to determine whether ascorbate could cause DSBs in the absence of metal 
catalysts. 
 
Figure 30 displays the results of the combination treatments 
assessed with the tail length variable, with averages derived from 9 
independent experiments. As expected both irradiation and ascorbate alone 
caused an increase in DSBs, irradiation increasing DSBs 2.1-fold over the 
control basal rate, and ascorbate increasing DSBs slightly more at 2.3-fold 
over untreated cells. The increases are presumably mediated by direct 
ionisation of DNA or water to cause ROS in the case of irradiation, and 
Fenton-reaction derived ROS in the case of ascorbate. In fact, the degree of 
DSBs in response to combination treatment is similar to individual 
treatments, only slightly more at 2.5-fold more than control.  
 
Cells treated with ascorbate in PBS rather than media did not have a 
significant increase in the amount of DSBs compared with control, only 
1.2-fold greater on average. This validated the need for trace transition 
metals in solution while treating with ascorbate, and supported the 
hydrogen peroxide mechanism. 
 
In Figure 31, the same comet tail combinations experiment is shown 
with the tail moment parameter. It follows roughly the same trend as that 
displayed in Figure 30, with ascorbate in PBS not increasing the degree of 
DSBs (only 1.1-fold greater than control), irradiation causing a moderate 
3.2-fold increase in DSBs, and ascorbate alone and in combination with 
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irradiation increasing the amount of DSBs more than irradiation, 5 and 3.8 
fold increases respectively. 
 
Consistent with other data, Figure 32 demonstrates that the percent 
tail DNA does not allow differentiation of treatment groups, with all groups 
being within 0.08-fold of each other. 
 
In conclusion, the neutral comet tail assay, a more direct measure of 
DSBs than H2AX, has a similar but not equal trend to that histone marker 
when considering the effect of combination ascorbate and irradiation 
treatment, at least in GL261 cells. H2AX (see ‘H2AX’) reports 
ascorbate increasing DNA damage, although to a slightly lesser degree than 
irradiation alone, and combination treatment increasing that measure more 
than either treatment individually. In contrast, the comet tail assay seems to 
support a more influential role for ascorbate. While combination treatment 
still causes the most DSBs in two of the three metrics used here (tail length 
and percentage tail DNA), ascorbate is shown as increasing DSBs to a 
greater degree than irradiation alone, in the context of the GL261 cells.  
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Figure 30. Single cell gel electrophoresis combination treatment tail lengths 
Single cell gel electrophoresis combination treatment tail lengths (fold change + Standard Error of 
the Mean [SEM]) with GL261 cells. Cells were exposed to 5mM of ascorbate for an hour in either 
PBS as a negative control (AA(-)) or DMEM media (AA). Combination cells were treated with 6 Gy 
of irradiation at 1-hour post-ascorbate. All cell treatments were then combined with agarose and 
applied to pre-agarose coated slides. Cell-containing agarose was allowed to dry for 30 minutes on 
slides before lysis. Graph contains data from 9 independent experiments, and each treatment group 
has a sample size of between 3 and 9 experiments. All treatments except ascorbate in PBS were 
statistically significantly higher than control (P values: 6 Gy 0.0191, AA in PBS 0.1337, AA 0.0361, 
AA+Gy 0.0023. Graph and statistics produced with Prism V6.0. 
 
 107 
 
 
 
Figure 31. Single cell gel electrophoresis combination treatment tail moments 
Single cell gel electrophoresis combination treatment tail lengths (fold change + Standard Error of 
the Mean [SEM]) with GL261 cells. Cells were treated as described in Figure 30. Graph contains 
data from 9 independent experiments, and each treatment group has a sample size of between 3 and 9 
experiments. Treatments except ascorbate, and ascorbate in PBS were statistically significantly 
higher than control (P values: 6 Gy 0.0343, AA in PBS 0.2717, AA 0.1055, AA+Gy 0.0104. Graph 
and statistics produced with Prism V6.0. 
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Figure 32. Single cell gel electrophoresis combination treatment percent tail DNA 
Single cell gel electrophoresis combination treatment percent tail DNA (fold change + Standard 
Error of the Mean [SEM]) with GL261 cells. Cells were treated as described in Figure 30. Graph 
contains data from 9 independent experiments, and each treatment group has a sample size of 
between 3 and 9 experiments. Treatments except ascorbate in PBS were statistically significantly 
higher than control (P values: 6 Gy 0.0015, AA in PBS 0.3253, AA 0.0089, AA+Gy 0.0013. Graph 
and statistics produced with Prism V6.0. 
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Analysis of DNA Damage In Vivo 
To achieve the ultimate aim of this project, namely to determine the 
radioprotective or radiosensitive role of ascorbate in vivo, the second 
objective of the project was to undertake similar DNA damage analysis to 
that done on in vitro cells on in vivo tissue. To this end, an intracranial 
murine model of GBM utilising GL261 cells was established in C57BL/6 
immunocompetent mice, mice were treated with the various treatments, and 
brains were harvested and markers of DNA damage assessed with 
immunofluorescence assays. Studying the same markers of DNA damage in 
vivo as investigated in vitro, in the same cell line, allows direct comparison 
of the particular DNA damage patterns. Therefore, it can then be 
determined whether ascorbate generates a pro-oxidant effect, enhancing 
radiotherapy, whether there is no effect on radiation-induced DNA damage, 
or whether the anti-oxidant activity inhibits radiotherapy. 
In Vivo Experimental Outline 
Two independent sets of experiments were run.  Mice were 
implanted with 2 μL of a 1.25x107/mL solution of cells, thus 2.5x104 cells 
total. Tumour tissue was collected after first a short-term 2-3hr exposure to 
ascorbate and radiation, and a longer-term 24hr exposure. Figure 33 is a 
diagrammatic representation of the experimental design timeline for these 
two experiments. In both experiments, mice underwent identical 
intracranial surgery once older than 8 weeks. Figure 34 compares the 
weights of mice on the day of intracranial surgery with weights on the day 
of treatment. Although there was some variation in mouse weights between 
these times, there was no significant difference in weights on the day of 
surgery and the day of treatment (paired t-test p value: 0.5329). Therefore, 
the tumour had not affected mice weights by the 18 or 19-day time point.  
 
In the short term treatment experiment, on day 18 post-surgery mice 
were weighed, assigned to a treatment group, and treated with either 
nothing, 2 mg/kg ascorbate, 13 Gy of irradiation (13 Gy irradiation setting 
results in a dose of ~10 Gy to the head (Grasso, Fabre et al. 2014)), or both 
treatments. Ascorbate was given either before or immediately after 
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irradiation. Mice were assigned to treatment groups such that all groups 
contained representation from each individual mouse box, to control for 
potential inter-box variability. All mice were culled between 1 and 2 hours 
after irradiation treatment. 
 
For the longer term treatment experiment, mice were weighed, 
assigned to a treatment group, and treated on day 19 post-surgery with 
either nothing, 2 mg/kg ascorbate, 13 Gy of irradiation (10 Gy to the head), 
or both treatments with ascorbate first, followed by irradiation. The longer 
term treatment experiment was staggered such that only one box and one 
mouse of each treatment group were treated on any given day, in order to 
eliminate any inter-box or inter-day bias. Mice were culled 24 hours post 
irradiation treatment. 
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Figure 33. In Vivo Experimental Plan 
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Figure 34. Experimental mouse weights 
Experimental mouse weights (male) on the day of surgery and the day of treatment. n=19. 
There was no significant difference between weights on the two days. Paired t test: P value= 
0.5329 
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Immunofluorescence Assay 
Once culled, mice were perfused with formalin and PBS, and brains 
were harvested and incubated overnight in formalin before being 
transferred to 70% ethanol. Brain tissue was processed, embedded in 
paraffin wax, and 5 μm sections were cut. 
Initial Immunofluorescence Results  
In order to determine whether the same pattern of DNA damage 
occurred in vivo as in vitro, immunofluorescence (IF) assays were carried 
out to attempt to detect and quantify H2AX signal from in vivo brain 
samples. Initial experiments used normal, non-tumour brain tissue areas and 
compared only brains that had received no treatment to brains that had 
received irradiation only. 
 
Figure 35 is a representative image of unirradiated, non-tumour 
brain tissue that was stained with H2AX. Brain tissue was processed as 
described in ‘Methods’, but blocked with 1% BSA, and stained with 
H2AX antibody at a dilution factor of 1:200. As predicted, very little 
H2AX positive punctae are visible, which indicates the relatively low 
levels of DNA damage present in the untreated mouse brain. DAPI stain, a 
commonly used marker of DNA, applied to the same tissue allows 
delineation of the boundaries of brain nuclei, and therefore gives an 
indication as to whether the H2AX is within the nucleus. Of the little 
numbers of punctae visible, a small proportion overlap with DAPI and can 
so be interpreted as true H2AX staining present within the nucleus. 
 
In Figure 36, a representative image of normal non-tumour, 
irradiated tissue, from the same experiment as Figure 35 and stained with 
H2AX is displayed. The mouse was involved in a short term treatment 
experiment and thus brain was harvested within 1-2 hours of irradiation 
(see ‘In Vivo Experimental Outline’). Relatively more H2AX positive 
regions can be identified in the irradiated brain sample as compared with 
the untreated sample. The large amount of punctae indicates the high 
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amount of DNA damage. As with the unirradiated brain sample, a 
proportion of punctae are visible within the nuclei. 
 
Nine independent immunofluorescence assays comparing control to 
irradiated brains were carried out using tissue from the two in vivo 
experiments described previously and staining for H2AX. All showed a 
comparable difference in DNA-damage-indicating positive stain between 
the two treatments, with irradiated brain displaying consistently more 
positive punctae (data not shown). This difference was identifiable by eye.  
 
In conclusion, a comparison of irradiated and non-irradiated brain 
stained with a fluorescent antibody marker of H2AX indicates that 10 Gy 
of irradiation to the murine head causes an observable increase in H2AX 
positive areas, strongly suggesting an increase in DNA damage caused to 
brain cells in this situation. 
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Figure 35. Normal, untreated brain tissue has little H2AX positive staining 
Representative images of normal untreated brain tissue stained with H2AX and DAPI. 
A. Normal non-tumour untreated brain tissue stained with H2AX and imaged at 100x objective. A 
large amount of background autofluorescence is visible as generalised green colour. A small amount 
of H2AX positive staining can be seen from basal DNA damage. B. The same field of view stained 
with DAPI nuclear stain. C. The same field of view displaying an overlay of H2AX and DAPI to 
discern punctae that are within nuclei. The scale bar of 200 pixels applies to all three images and 
corresponds to 12.9 μm. Images A and B were unaltered. The brightness on Image C was increased 
to allow visualisation of H2AX positive punctae within the bounds of DAPI nuclear stain. Produced 
using the ImageJ FigureJ plugin. 
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Figure 36. Normal, irradiated brain tissue has an increase in basal H2AX positive staining 
Representative images of normal irradiation treated brain tissue stained with H2AX and DAPI. 
A. Normal non-tumour brain tissue irradiated with 10 Gy as described in methods, stained with 
H2AX and imaged at 100x objective. As with Figure 35, a large amount of background 
autofluorescence is visible as generalised green colour. H2AX positive punctae can be seen, to a 
relatively higher degree than Figure 35. B. The same field of view stained with DAPI nuclear stain. 
C. The same field of view displaying an overlay of H2AX and DAPI to discern punctae that are 
within nuclei. H2AX positive punctae are visible in and around DAPI positive nuclei. The scale bar 
of 200 pixels applies to all three images and corresponds to 12.9 μm. Images A and B were 
unaltered. The brightness on Image C was increased to allow visualisation of H2AX positive 
punctae within the bounds of DAPI nuclear stain. Produced using the ImageJ FigureJ plugin. 
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Troubleshooting 
Due to the abundance of background fluorescence seen in the initial 
IF experiments, many methods were tried in order to improve the clarity of 
IF pictures and thus data, to allow potential quantification of the results 
described. This troubleshooting was carried out comparing control to 
irradiated normal brain sections. 
 
Table 6 details the different alterations to the H2AX IF protocol 
that were attempted. No alteration decreased autofluorescence to allow 
determination of H2AX positive punctae from generalised 
autofluorescence. The only alterations that did decrease autofluorescence 
were an alternative AlexaFluor 647 conjugated H2AX antibody, which 
revealed no fluorescence unless at high exposure, in which case 
fluorescence was generalised and red, or treatment after antibody 
incubation with a 0.1% solution of Sudan Black, which reduced all 
fluorescence save fluorescence of blood and blood vessels. 
 Table 6. Optimisation of Immunofluorescence Assay 
Alteration Explanation  Outcome 
Antibody  Titrations. 
H2AX antibody was used at 
the following dilution factors 
(concentration): 
1:2000   (12.5 ng/mL) No antibody concentration decreased 
autofluorescence. Titrations higher than 1:50 
appeared to cause positive signal to be brighter. 
1:1000   (25 ng/mL) 
1:500     (50 ng/mL) 
1:200     (125 ng/mL) 
1:100     (250 ng/mL) 
1:50       (500 ng/mL) 
1:20       (1.25 μg/mL) 
 Choice of Fluorophore. 
488 and 647 conjugated 
H2AX antibody were used 
488: Green fluorescence is 
overcome by tissue 
autofluorescence. 
647: Fluoresces in the red 
channel.  
All concentrations of 488 antibody caused 
autofluorescence (see above). 
Dilutions of 647 antibody (1:1000, 1:500, 1:250, 
1:50, 1:20), did not show fluorescence in the Cy5 
filter set without extremely high exposure. 
Exposure of high magnitude caused a 
generalised red fluorescence. The 647 was 
validated and was functional via flow cytometry 
(data not shown). 
 Incubation Overnight at 4oC and 
1 hour at room temperature. 
Both methods of antibody incubation were 
similar. Neither method decreased 
autofluorescence.  
Antigen retrieval Three types of antigen 
retrieval 
10mM sodium citrate, pH 6 No antigen retrieval method decreased 
autofluorescence. EDTA buffer, pH 8 
Tris EDTA buffer, pH 9 
 Time and Temperature Varied the time and 
temperature of antigen retrieval 
from 95oC for 10 minutes to 
85oC for 60 mins. 
1
1
8
 
 Agitation  During processing of slides Investigated agitating coplin 
jars during ethanol and wash 
steps. 
Did not decrease autofluorescence. 
Block  
 
Concentration Changed the concentration of 
block from 1% to 5% BSA. 
All blocking methods were similar. Neither 
method decreased autofluorescence. 
 Incubation Investigated overnight at 4oC 
and 1 or 2 hours at room 
temperature. 
 Donkey serum Attempted 2% donkey serum 
with 1% BSA block. 
Sodium borohydride An additional antigen 
retrieval chemical 
Added a 0.5% sodium 
borohydride retrieval step 
Did not decrease autofluorescence. 
Sudan Black Commonly used to quench 
tissue autofluorescence 
Added a 1% Sudan Black in 
TBST after antibody 
incubation 
Decreased autofluorescence, yet also eliminated 
all signal other than red blood cells. 
Wash buffer Phosphate Buffered Saline 
(PBS) or Tris Buffered Saline 
and Tween-20 (TBST) 
Switched to from PBS to 
TBST for washes, dilution of 
BSA, dilution of antibodies 
Did not decrease autofluorescence. 
Confocal Looked at some slides with a 
confocal microscope 
Try and determine whether the 
H2AX staining was within 
the nucleus 
Allowed a more detailed image of the 
fluorescence but could not confirm that H2AX 
positive signalling was contained within the 
nuclei, as indicated by DAPI staining 
1
1
9
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Tumour Immunofluorescence 
Due to time constraints, it was not possible to identify a solution 
that would eliminate autofluorescence without blocking true fluorescence, 
before progressing to an attempted analysis of tumour tissue. 
 
Tumours were located by sectioning 2mm in from the midline of 
each hemisphere. Some regions of tumour were more easily identifiable by 
areas of necrosis. Slides containing tumour tissue were processed through 
an immunofluorescence protocol described in ‘Methods’ and imaged as 
soon as possible, always within 48 hours. 
 
DNA-bound DAPI stain was used to identify regions of tumour, 
indicated by the densely packed and heterogeneous nature of tumour nuclei. 
Figure 37 characterises nuclei with representative pictures of DAPI stained 
tumour nuclei taken at 3 different objectives. These images confirm 
presence of established GBM tumour in mouse brains in response to GL261 
inoculation. 
 
H2AX and 8-OHdG was used to stain tumour tissue of each 
treatment in order to establish the specific types of DNA damage caused by 
ascorbate, irradiation or combinations of both in either sequence. 
 
Figures 38 to 42 show a sequence of representative images of each 
treatment group covered in these experiments, stained with H2AX and 
DAPI. Considerable background autofluorescence impeded identification of 
subtle and quantifiable trends, although overall differences can be 
discerned. It was discovered that both ascorbate and irradiation alone 
caused an increase in H2AX positive punctae in brain tumour tissue, (Fig 
39 and 40). Interestingly, in the groups of mice that received both ascorbate 
and irradiation treatment, both the group that were given ascorbate as pre-
treatment and the group that received ascorbate immediately after 
irradiation treatment, apparently less H2AX positive areas are observable 
(Figure 41 and 42). The two groups that received both treatments were 
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comparable in the low degree of H2AX staining seen, and potentially on 
par with the basal level of H2AX observed in control brain cells (Figure 
38). 
 
Figures 43 to 47 are representative images of the tumour brain tissue 
of each treatment group, stained with 8-OHdG and DAPI. Again, 
background autofluorescence hampers observation, yet some differences 
can be seen. For instance, ascorbate only treatment (Figure 44) in general 
displays distinctive, widespread 8-OHdG staining throughout the tumour 
tissue that is of a noticeably different quality to other treatment groups, 
even ascorbate combination treated tissue (Figure 46 and 47). As with the 
H2AX marker, irradiation alone caused an increase in 8-OHdG positive 
punctae in brain tumour tissue, (Fig 43). In the groups of mice that received 
both ascorbate and irradiation treatments, again, less 8-OHdG positive areas 
are observable (Figure 46 and 47). 
 
In summary, preliminary in vivo evidence, although not fully 
optimised, indicates that in both H2AX and 8-OHdG markers of damage 
to DNA, neither ascorbate pre or post irradiation treatment functions as a 
prooxidant and increases DNA damage caused by irradiation. On the 
contrary, combination treatments may in fact decrease the DNA damaging 
effect of irradiation as measured with these two markers, and thus potential 
therapeutic potential.  
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Figure 37. Representative Images of DAPI stained tumour tissue from untreated brain. 
A and B. Untreated tumour brain tissue stained with DAPI and imaged at 10x objective. The scale 
bar of 200 pixels corresponds to 129 μm C and D. Untreated tumour brain tissue stained with DAPI 
and imaged at 20x objective. The scale bar of 200 pixels corresponds to 64.5 μm. E and F. Untreated 
tumour brain tissue stained with DAPI and imaged at 100x objective. The scale bar of 200 pixels 
corresponds to 12.9 μm. All images were unaltered for contrast and brightness. Produced using the 
ImageJ FigureJ plugin. 
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Figure 38. Representative Images of H2AX and DAPI stained tumour tissue from untreated 
brain 
A. Untreated control tumour brain tissue stained with H2AX and imaged at 100x objective. A large 
amount of background autofluorescence is visible as generalised green colour. Some H2AX 
positive punctae can be seen, to a relatively lower degree than Figure 39. B. The same field of view 
stained with DAPI nuclear stain. C. The same field of view displaying an overlay of H2AX and 
DAPI to discern punctae that are within nuclei. The scale bar of 200 pixels corresponds to 12.9 μm. 
Images A and B were unaltered; the brightness of the composite Image C was increased. Produced 
using the ImageJ FigureJ plugin. 
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Figure 39. Representative Images of H2AX and DAPI stained tumour tissue from ascorbate 
treated brain 
A. Ascorbate treated tumour brain tissue stained with H2AX and imaged at 100x objective. A large 
amount of background autofluorescence is visible as generalised green colour. H2AX positive 
punctae are visible, to a greater degree than Figure 38. B. The same field of view stained with DAPI 
nuclear stain. C. The same field of view displaying an overlay of H2AX and DAPI to discern 
punctae that are within nuclei. The scale bar of 200 pixels corresponds to 12.9 μm. Images A and B 
were unaltered; the brightness of the composite Image C was increased. Produced using the ImageJ 
FigureJ plugin. 
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Figure 40. Representative Images of H2AX and DAPI stained tumour tissue from irradiated 
brain 
A. Irradiation treated tumour brain tissue stained with H2AX and imaged at 100x objective. A large 
amount of background autofluorescence is visible as generalised green colour. H2AX positive 
punctae are visible, to a greater degree than Figure 38. B. The same field of view stained with DAPI 
nuclear stain. C. The same field of view displaying an overlay of H2AX and DAPI to discern 
punctae that are within nuclei. The scale bar of 200 pixels corresponds to 12.9 μm. Images A and B 
were unaltered; the brightness of the composite Image C was increased. Produced using the ImageJ 
FigureJ plugin. 
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Figure 41. Representative Images of H2AX and DAPI stained tumour tissue from ascorbate 
pre-treated, irradiated brain 
A. Ascorbate pre-treatment and irradiation treated tumour brain tissue stained with H2AX and 
imaged at 100x objective. A large amount of background autofluorescence is visible as generalised 
green colour. H2AX positive punctae are visible, but to a lesser degree than Figure 39 or Figure 40. 
B. The same field of view stained with DAPI nuclear stain. C. The same field of view displaying an 
overlay of H2AX and DAPI to discern punctae that are within nuclei. The scale bar of 200 pixels 
corresponds to 12.9 μm. Images A and B were unaltered; the brightness of the composite Image C 
was increased. Produced using the ImageJ FigureJ plugin. 
 
 127 
 
 
 
Figure 42. Representative Images of H2AX and DAPI stained tumour tissue from irradiated, 
ascorbate post-treated brain 
A. Irradiation and ascorbate post-treatment treated tumour brain tissue stained with H2AX and 
imaged at 100x objective. A large amount of background autofluorescence is visible as generalised 
green colour. Very little, if any H2AX positive punctae are visible. B. The same field of view 
stained with DAPI nuclear stain. C. The same field of view displaying an overlay of H2AX and 
DAPI to discern any punctae that are within nuclei. The scale bar of 200 pixels corresponds to 12.9 
μm. Images A and B were unaltered; the brightness of the composite Image C was increased. 
Produced using the ImageJ FigureJ plugin. 
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Figure 43. Representative Images of 8-OHdG and DAPI stained tumour tissue from untreated 
brain 
A. Untreated control tumour brain tissue stained with 8-OHdG and imaged at 100x objective. A large 
amount of background autofluorescence is visible as generalised green colour. Very little, if any 8-
OHdG positive punctae can be seen. B. The same field of view stained with DAPI nuclear stain. C. 
The same field of view displaying an overlay of 8-OHdG and DAPI to discern any punctae that are 
within nuclei. The scale bar of 200 pixels corresponds to 12.9 μm. Images A and B were unaltered; 
the brightness of the composite Image C was increased. Produced using the ImageJ FigureJ plugin. 
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Figure 44. Representative Images of 8-OHdG and DAPI stained tumour tissue from ascorbate 
treated brain 
A. Ascorbate treated tumour brain tissue stained with 8-OHdG and imaged at 100x objective. Some 
background autofluorescence is visible as generalised green colour. Many 8-OHdG positive punctae 
can be seen, much more than in Figure 43. B. The same field of view stained with DAPI nuclear 
stain. C. The same field of view displaying an overlay of 8-OHdG and DAPI to discern punctae that 
are within nuclei. The scale bar of 200 pixels corresponds to 12.9 μm. Images A and B were 
unaltered; the brightness of the composite Image C was increased. Produced using the ImageJ 
FigureJ plugin. 
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Figure 45. Representative Images of 8-OHdG and DAPI stained tumour tissue from irradiation 
treated brain 
A. Irradiation treated tumour brain tissue stained with 8-OHdG and imaged at 100x objective. A 
large amount of background autofluorescence is visible as generalised green colour. Some 8-OHdG 
positive punctae can be seen, more than control cells in Figure 43, but apparently less than ascorbate 
treated cells in Figure 44. B. The same field of view stained with DAPI nuclear stain. C. The same 
field of view displaying an overlay of 8-OHdG and DAPI to discern punctae that are within nuclei. 
The scale bar of 200 pixels corresponds to 12.9 μm. Images A and B were unaltered; the brightness 
of the composite Image C was increased. Produced using the ImageJ FigureJ plugin. 
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Figure 46. Representative Images of 8-OHdG and DAPI stained tumour tissue from ascorbate 
pre-treated, irradiated brain 
A. Ascorbate pre-treatment and irradiation treated tumour brain tissue stained with 8-OHdG and 
imaged at 100x objective. Some background autofluorescence is visible as generalised green colour. 
A small amount of 8-OHdG positive punctae can be seen, less than Figure 44 or 45. B. The same 
field of view stained with DAPI nuclear stain. C. The same field of view displaying an overlay of 8-
OHdG and DAPI to discern punctae that are within nuclei. The scale bar of 200 pixels corresponds to 
12.9 μm. Images A and B were unaltered; the brightness of the composite Image C was increased. 
Produced using the ImageJ FigureJ plugin. 
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Figure 47. Representative Images of 8-OHdG and DAPI stained tumour tissue from irradiated, 
ascorbate post-treated brain 
A. Irradiation and ascorbate post-treatment treated tumour brain tissue stained with 8-OHdG and 
imaged at 100x objective. A little background autofluorescence is visible as generalised green colour, 
although most green fluorescence is from blood and blood vessels. Very little, if any 8-OHdG 
positive punctae can be seen, to a relatively lower degree than Figure 44 or 45. B. The same field of 
view stained with DAPI nuclear stain. C. The same field of view displaying an overlay of 8-OHdG 
and DAPI to discern punctae that are within nuclei. The scale bar of 200 pixels corresponds to 12.9 
μm. Images A and B were unaltered; the brightness of the composite Image C was increased. 
Produced using the ImageJ FigureJ plugin. 
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Chapter 4: Discussion 
GBMs are notoriously radiation and chemotherapy resistant. In this 
investigation it was confirmed that it is possible to radiosensitise GBM cells 
in vitro with ascorbate, with respect to three indicators of DNA damage, 
H2AX, 8-OHdG, and DSBs. However, in vivo, ascorbate does not appear 
to increase the effectiveness of irradiation in causing an increase in DNA 
damage, as indicated by H2AX or 8-OHdG; in fact it may potentially 
decrease irradiation’s efficacy. A caveat to this result is the preliminary 
nature of in vivo results. 
In Vitro 
H2AX 
In vitro results from this study that show ascorbate successfully 
enhanced DNA damage, measured with H2AX in GBM cells. This 
complements findings from other studies conducted in our lab. 
 
Herst et al. showed that H2AX was increased in response to 5mM 
ascorbate and 6Gy of irradiation too, although that assay was done in the 
primary cell line 0906 and compared with normal astrocytes, as a measure 
of the selectivity of treatment to cancer cells. Interestingly, in that study, 
ascorbate increased the proportion of H2AX positive 0906 cells to a 
greater degree than irradiation alone, a damage trend more similar to 8-
OHdG and the comet tail results than H2AX in this investigation. 
 
In a more recent paper, our lab investigated the effect of 
radiosensitising effect of ascorbate on a panel of both cell lines and primary 
cells, including two of the cells used in this study, T98Gs and 1003s. That 
study, which used an identical treatment time of 2 hours as used here, gave 
comparable results. 
 
The T98G cell line was most ascorbate resistant, with a less than 2-
fold increase in H2AX, while irradiation and combination treatment gave 
higher, 3.5-fold increases. This is similar to the percent positive results seen 
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here of 1.1, 3.5, and 2.5-fold percent positive increases for ascorbate, 
irradiation, and combination treatment respectively in T98G cells. 
 
In contrast, 1003 results in this 2014 paper showed a consistent, just 
over 2-fold increase in H2AX staining 2 hours after any of the three 
treatments, while this investigation had the same treatments causing 2.5, 2, 
and 3-fold increases in H2AX for irradiation, ascorbate and combination 
respectively. A possible reason for the difference in results here between 
this investigation and that published is the further optimisation of the 
protocol that has been carried out since those experiments were conducted. 
 
In Grasso et al, GL261 cells were used to investigate the 
radiosensitising effect of ascorbate, in a protocol very similar to that used 
here. H2AX positive staining was determined, and with percent positive 
cells, found to be approximately 5, 6, and 9-fold greater than control 
fluorescence at 2 hours post treatment for irradiation, ascorbate, and 
combination treatments respectively. The trend differs from what is 
reported here (see ‘H2AX’), as this study found a slightly less extreme 
increase in H2AX with all treatments, and opposite outcomes in response 
to ascorbate and irradiation alone. In contrast with Grasso et al, these 
H2AX experiments report irradiation provoking more H2AX than 
ascorbate, and fold increases of 3.1, 3 and 4 fold for irradiation, ascorbate, 
and combination. As with H2AX measurement in T98G and 1003 cells, 
different results may be attributable to subtle differences in protocol 
development between the two tests. 
 
In conclusion, H2AX results here compared with past experiments 
done in our lab are broadly similar. Although sometimes variable by cell 
line, and subject to alterations in protocol, the overall trend stands. 
Ascorbate acts as a radiosensitiser and so together with irradiation causes a 
greater increase in H2AX, and thus DNA damage, than individual 
treatments. 
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8-OHdG 
In this investigation, ascorbate enhanced DNA damage in GBM 
cells as indicated by the 8-OHdG marker. As well H2AX, 8-OHdG is 
another DNA damage marker that was used in this study. To our 
knowledge, 8-OHdG has not been used specifically to study the DNA 
damaging effects of prooxidant ascorbate in GBM cells, although it has 
been used in assessing the efficacy of cancer treatments, including GBM, as 
a prognostic marker, a test of antioxidant capacity (Gonenc, Hacisevki et al. 
2012), and investigating the prooxidant effects of ascorbate in many 
contexts, including cancer (Valavanidis, Vlachogianni et al. 2009). 
 
An example of surveying the effect of ascorbate’s prooxidation 
effect with 8-OHdG is an investigation by (Poljšak, Gazdag et al. 2005), 
who were looking for a pre-treatment that would protect against 
chromium(VI) mediated damage in a yeast model. Interestingly, in vitro, 
ascorbate acted as an antioxidant in the absence of chromium, but as a 
concentration dependent prooxidant in its presence, as measured by 8-
OHdG. Yet in vivo, ascorbate decreased cytotoxicity and acted in its radical 
scavenging role, an effect the authors ascribed to increased cytosol 
reduction and better scavenging abilities. This result mirrors that found in 
this investigation with opposite in vitro and in vivo results, and validates 8-
OHdG as an accurate and suitable marker for detecting ascorbate’s 
prooxidant activity. 
 
8-OHdG has also been successfully used in investigating prognostic 
outcomes in cancer studies. One example studied its correlation with 
survival and tumour grade in ovarian cancer, finding that high incidence of 
8-OHdG in serum and tumour tissue highly predicted tumour grade and was 
negatively correlated with survival (Pylväs, Puistola et al. 2011). 
 
Another study was in glioma (Lian, Zhang et al. 2014), and 
examined the relationship between 8-OHdG marking and autophagy, as 
indicated by microtubule-associated protein 1 light chain-3B (LC3B). Tests 
used both ex vivo tumours and were validated with the U87 cell, a standard 
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GBM cell line. As with the ovarian cancer study, tumour grade was 
positively correlated with levels of 8-OHdG. Grade and 8-OHdG also 
predicted increased LC3B, an indicator of autophagy. Interestingly, 
prevention of autophagy with an inhibitor caused a strong increase in ROS 
production. 
 
These two prognostic cancer study results are inverse to that 
hypothesised in this investigation, where an increase in 8-OHdG correlates 
with DNA damage and is so inferred to predict the effectiveness of 
treatment, rather than the effectiveness of tumour malignancy. It may be, 
however, that below a certain threshold of 8-OHdG, the marker is 
associated with increased tumour mutation and aggressiveness, while above 
that threshold 8-OHdG indicates excessive DNA damage that the cell is 
unable to repair and will cause cell death. 
 
Although H2AX as a marker of DNA damage, specifically DSBs, 
had been used extensively in our lab prior to this investigation, 8-OHdG as 
a marker of oxidative stress was newly introduced for this study. Thus past 
results cannot be exactly compared, yet nonetheless interesting parallels can 
be drawn. For instance, although measurement of ROS load was not 
ventured here, there are interesting trends between ROS load, as 
investigated in Castro et al, and 8-OHdG levels in response to the same 
doses of ascorbate, at least in T98G and 1003 cells. This comparison is 
consistent with ascorbate’s mechanism of action as a ROS mediated DNA 
damager. 
 
In that paper, T98Gs displayed an approximately 2-fold difference 
in ROS production in response to ascorbate versus hydrogen peroxide, with. 
5 mM of ascorbate producing double the ROS load to 50 μM of hydrogen 
peroxide. In a similar way, T98Gs in this investigation had greater 
susceptibility to ascorbate than to hydrogen peroxide as judged by the 
appearance of 8-OHdG; ascorbate only had a 5-fold increase in 8-OHdG, 
while hydrogen peroxide caused a 3.5-fold increase. 
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Similarly, ROS load results followed the same trend as 8-OHdG 
occurrence in 1003 cells, and the opposite trend to the T98G cells. Castro et 
al. showed that 1003 cells increased ROS more in response to hydrogen 
peroxide than ascorbate, although the difference was only in the region of 
20%. Likewise, 8-OHdG measurements of 1003 cells here found that 
hydrogen peroxide caused greater incidence of the marker compared with 
ascorbate, although in this case, the treatment difference was closer to 2-
fold. These similarities can be interpreted as corroboration of the 
antioxidant capacity and specific vulnerability to ascorbate and hydrogen 
peroxide in these cells. 
Comet Tail Assay 
The comet tail assay, as a measure of DNA strand breaks, is used in 
a variety of applications, such as investigating the toxicity of environmental 
substances, basic research into DNA damaging agents, clinical responses, 
and even as a test of the suitability of sperm for IVF (in vitro fertilisation) 
treatments. It has also begun to be investigated as a prognosis marker for 
cancer. 
 
Like the other two in vitro assays used here, the comet tail assay has 
also been applied to investigation of ascorbate’s prooxidant capacity and 
ability to induce DNA strand breaks. Using the comet tail assay, Ullah et al. 
(2010) also showed the prooxidant effect of ascorbate in lymphocytes, and 
that it could be inhibited by the addition of iron and copper chelators, 
highlighting the importance of these metals. The authors proposed therefore 
that differential availability of metal catalysts in cancer as opposed to 
regular cells, may be a mechanism of selectivity seen in some experiments. 
The comet tail assay is known to be applicable to all eukaryotic cells, yet 
specific reporting of ascorbate’s prooxidant effect from this paper and 
others (Duarte, Almeida et al. 2007; Yen, Duh et al. 2002) with this assay is 
a validation of its use here. 
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There are also studies that have used the comet tail assay to assess 
cancer treatments potential to cause DNA damage, including those for 
GBM (Chakravarti, Erkkinen et al. 2006). For instance, Lu et al. (2010) 
published an investigation into the effect of a cytotoxic agent danthron in 
GBM 8401 cells, that found comet assay tail lengths were significantly 
lengthened in response. Another study (Hardee, Marciscano et al. 2012) 
used neurosphere cultures of GL261 cells to measure alterations in DNA 
damage from irradiation by prior treatment with a transforming growth 
factor-β (TGFβ) inhibitor. That study found that treating GBM cells with 
inhibitor enhanced the effect of fractionation alone in increasing DNA 
damage, which points to the DNA damage response as a key mediator of 
radioresistance in GBM. 
 
As for our own lab’s experiments, the comet tail was newly 
established during this investigation, and so cannot be directly contrasted 
with our previous results. However, some comparisons can be made with 
previous studies involving H2AX. This comparison is relevant due to the 
similarity in reported function as indicators of DSBs. 
 
One interesting example of difference is cell repair after exposure to 
ascorbate. As previously described, an optimisation experiment for the 
comet tail assay was an ascorbate treatment time course including 
measurement of DSB repair up to 24 hours post 1-hour ascorbate exposure. 
In that assay, it was found that by 8 hours after treatment, the number of 
DSBs had regressed to approaching control levels (see ‘Ascorbate Time 
Course’). This varies with results displayed in (Castro, McConnell et al. 
2014) which reported many cell lines with impaired DSB repair even at 24 
hours post-ascorbate, based solely on the resolution of H2AX. However, 
in that paper the GL261 response was not measured, which, as a murine 
GBM cell line may possess different cell repair abilities. Furthermore, as 
mentioned, differences between the assays prevent direct contrast. 
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An additional assay that could have been carried out in this study is 
the comet tail assay on ex vivo samples of brain tumour and normal tissue. 
Although here the comet tail assay was only performed on in vitro cells, use 
of the assay on ex vivo tissue is not uncommon (Tice, Agurell et al. 2000) 
and would only require homogenisation of tissue into individual cells. 
 
Another alteration to this assay that may have been informative is 
the common version involving an alkaline DNA unwinding step, which 
measures the degree of single strand breaks (SSBs). That assay was 
attempted once, although was not optimised (data not shown). 
 
The neutral version of the comet tail assay was focussed on for two 
reasons. Firstly, as previously mentioned, DSBs are considered the most 
cytotoxic DNA alteration, and more likely to cause cell death than the 
relatively easier repaired SSBs. Secondly, in an alkaline assay, cell cycle 
status contributes to the comet parameters, since single strand breaks arise 
as a normal part of cell replication (Fairbairn and O'Neill 1995). Only 
undertaking DSB measurements should have limited this cell cycle effect. 
 
As mentioned, the comet tail assay was newly established in our lab 
by the author, and despite optimisation may benefit from further alterations 
to the protocol. In the experiments presented here, cell nuclei comets were 
all analysed manually with a comet tail plugin for the ImageJ software, and 
so will contain inherently more variability than if analysed automatically. 
Although more sophisticated and automated programs are available, they 
are expensive and require specific microscope imaging software, so were 
not used. 
In Vivo 
Immunofluorescence 
This report’s results regarding immunofluorescence assays of 
tumour brain tissue, although preliminary, complement findings made in 
our own lab. Those findings, which contradicted our other findings on the 
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radiosensitising role of ascorbate in vitro, originally provoked this 
investigation, and are corroborated by the initial details given here. 
 
Grasso et al. (2014) used a GL261 murine model of GBM to 
investigate the potential radiosensitising role of ascorbate that had been 
evident in vitro. Unexpectedly, as explained in ‘Introduction’, tumour-
bearing mice that were treated with both 4.5 Gy of irradiation and 1g/kg of 
ascorbate had significantly worse survival than those mice treated with 
ascorbate alone. These data suggested that instead of making the tumour 
more sensitive to radiation, ascorbate in fact protected the tissue from 
radiation damage. 
 
If ascorbate does in fact act as radio-protector in vivo, that would 
mesh with results presented here. Overall survival was not the focus of this 
study, but the amount of DNA damage correlates with the efficacy of 
treatment and therefore clinical relevance. It was found in this investigation 
(see ‘Tumour Immunofluorescence’) that although both ascorbate and 
irradiation individually caused a noticeable increase in both H2AX and 8-
OHdG, indicating DNA damage, that fluorescence was strongly limited by 
combination treatments. Further work should be carried out to fully 
optimise the protocol detailed and develop a method of quantification that 
was not possible here. 
 
Confounding Factors 
As mentioned in the introduction, there are a variety of ideas 
surrounding the mechanism of ascorbate’s action. Many in vitro studies 
investigate the prooxidant mechanism that causes DNA damage. However, 
there are a variety of other factors at play, such as hypoxia, that could 
complicate ascorbate’s function and causing these conflicting results in 
vitro and in vivo results.  
 
Environmental conditions, or the cancer microenvironment, are 
pivotal to the effect of a given treatment on cancer. Generally, and in this 
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study, in vitro cultures are kept at 20% oxygen and have their media 
changed regularly to ensure a constant supply of nutrients. Cells are also 
regularly passaged to guarantee sufficient space. 
 
These controlled conditions are in stark contrast to that found in the 
in vivo environment, where oxygen levels can vary between 5 and less than 
1% (Herst et al). Like many other solid forms of cancer, GBM contains 
hypoxic regions within the tumour mass. This hypoxia is the result of rapid 
cell growth and disorganised, subpar angiogenesis. Areas of hypoxia 
influence tumour outcomes in many ways. For example, hypoxic regions 
are better able to resist radiation because of their requirement for oxygen 
and and chemotherapy for the lack of functioning blood vessel access. 
 
In relation to the effect of ascorbate on tumours, a factor that should 
be considered is ascorbate’s influence on HIF1a, as described in ‘Ascorbate 
as a Co-factor’. Although some experiments have shown ascorbate 
supplementation decreased HIF1 activity, the process may be more 
complicated. For example, there is some evidence that H2O2 can inhibit 
HIF1 hydroxylases (Kuiper and Vissers 2014), which would thus increase 
the activity of HIF1 and so cause induction of pro-survival factors. 
Ascorbate can create hydrogen peroxide by the mechanism outlined in Eq 
7/8 (see ‘Ascorbate as a Prooxidant’), and so could potentially contribute to 
this effect, in an opposing action to its established behaviour as a metal 
reducing, HIF1 inactivating co-factor. 
 
Moreover, recent evidence has detailed how ascorbate’s oxidation 
reaction is strongly dependent on oxygen, such that when samples were 
flushed with argon to limit oxygen, peak creation of ascorbate radicals was 
nearly 3-fold lower than oxygen-containing solutions (Boatright 2015). 
 
A potential treatment development that might be investigated is to 
increase the oxygen concentration in tumours, by methods such as 
hyperbaric oxygen chambers (Moen and Stuhr 2012). If combined with 
ascorbate in cancer therapy, increased oxygen could lessen hypoxia’s 
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confounding effects on ascorbate’s mechanism and lead to determination of 
a factor that causes these in vitro and in vivo differences. Initial 
investigations of the effect of supplemental oxygen in vivo models prior to 
clinical practice could be undertaken by a research lab with those particular 
facilities. 
 
Another possibility is that ascorbate is not even being converted to 
hydrogen peroxide at all in vivo. Because ascorbate in its oxidised form is 
taken up by SVCT transporters, cells that upregulate the transporters may 
be importing ascorbate before the conversion has even taken place, a 
conversion that happens in the extracellular space. This may be causing 
ascorbate to act as a traditional antioxidant and so limit the cytotoxicity of 
irradiation (Grasso, Fabre et al. 2014; McConnell and Herst 2014). Further 
investigation could measure the expression of transporters at time points 
after inoculation of murine models with GBM, or correlate the expression 
of transporters in ex vivo primary tumour cells with eventual survival. This 
would fill in current gaps in our knowledge of ascorbate’s transport in the 
particular context of GBM.  
 
Of course it is also possible that ascorbate has its effect in a 
complex multifaceted way that includes these factors and more. The 
conflicting results, even between in vivo studies, suggests that much more 
investigation is needed in order to work out the subtleties of ascorbate’s 
variable effects in the animal context. 
Selectivity 
Some have suggested that not only does ascorbate cause DNA 
damage and cell death in cells, but that this effect is specific to cancerous 
cells. This would be of great clinical significance if correct, as it would 
allow for high-dose ascorbate to cause cytotoxicity in cancerous cells while 
avoiding death to regular healthy cells. Many cancer therapies cause 
damage to healthy cells, but that disadvantage is considered to be 
outweighed by the effective cytotoxicity to cancer cells. If ascorbate could 
be shown to have cytotoxic effect against cancer while acting in a non-
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harmful way to normal cells, that would give a strong advantage to its use. 
There are reasons to accept this claim of specificity, although our lab group 
has not seen evidence of it thus far (Castro, McConnell et al. 2014). 
 
For example, cancerous cells already have significant DNA 
anomalies and mutations that have caused the initial uncontrolled 
replication. Strategies to detoxify in response to oxidative stress will also be 
compromised. Secondly, cancer cells’ higher glucose requirements for 
excessive growth cause up-regulation of GLUT transporters and are more 
likely to take up the oxidised ascorbate DHA. DHA in high doses has also 
shown to be cytotoxic. Thirdly, cancerous cells have 10-1000 times less 
catalase than regular healthy cells (Benade, Howard et al. 1969), and so will 
be less able to inhibit cytotoxicity caused by ascorbate-created hydrogen 
peroxide. And finally, cancer cells may contain higher levels of metals 
available to catalase prooxidant reactions (Ullah, Khan et al. 2010). 
 
These hypothetical reasons seem to have been borne out with actual 
evidence of selectivity in some in vitro (Benade, Howard et al. 1969; Bram, 
Froussard et al. 1980; Noto, Taper et al. 1989) and in vivo (Pierson and 
Meadows 1983; Tsao 1991; Varga and Airoldi 1983) studies. Although, 
significantly, these studies were not carried out in GBM or brain cells, and 
so are not directly comparable the particular GBM situation. 
 
In the face of this, it would have been informative to undertake all 
tests in parallel with non-malignant brain cells to test any potential 
specificity between tumorigenic and non-tumorigenic cells. However, this 
would have required purchase of a new cell line or technically difficult 
immortalisation of primary astrocytes for comparison.  
 
For the in vivo experiments, non-tumour tissue acted as that normal 
cell equivalent, and initial results allowed some assessment of whether 
ascorbate’s action was selective to cancerous cells. In experiments carried 
out for this investigation, no differences could be seen in the presence of 
H2AX and 8-OHdG punctae in response to ascorbate in tumour compared 
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with non-tumour tissue (images not shown). Although clearly if ascorbate is 
not confirmed to function at all as a prooxidant cancer therapy in vivo, then 
the subject of selectivity is insignificant. 
The Role of Metals 
A key consideration in the DNA damaging effects of ascorbate is 
the catalytic role of transition metals. There is some question over whether 
there even enough catalytically available metal in vivo to cause the effects 
we expect to see, or even whether metals are as important in this case as 
expected (Gonzalez 2014; Halliwell and Gutteridge 1986). If they are, 
differences in metal concentrations are a possible explanation for the 
different effects seen in vitro and in vivo in this and other experiments.  
 
The data produced in this study supports a significant role for metals 
in the ascorbate reaction, as displayed in the large difference in production 
of DNA DSBs in response to ascorbate when treated in PBS versus in 
DMEM media (see ‘Combination Treatments’). 
 
Carr and Frei’s (Carr and Frei 1999) meta-analysis of cell culture 
studies that measured markers of DNA, protein, and lipid oxidative 
damage, concluded that in general, ascorbate performed in type and acted 
as antioxidant. However, in studies with added metal, ascorbate 
transformed into a pro-oxidant and increased markers of stress such as 
single stranded breaks in the single cell gel electrophoresis (See ‘Comet 
Tail Assay’). 
 
Yet it is dangerous to unquestioningly extrapolate from in vitro to in 
vivo metallic conditions. Although cell culture media contains sufficient 
free metals to catalyse the required Fenton/Haber-Weiss reaction, those 
same levels of metal might not be present in vivo, preventing the full 
potential of the reaction. Some have pointed out that although the body is 
filled with trace metals, very little of these are catalytically available, due to 
binding to molecules such as ferritin (Carr and Frei 1999; Gonzalez 2014). 
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But if this is found to be the case, it may be straightforward to fix by 
supplementing the diets of patients with available metals (McCarty and 
Contreras 2014). For example, Tsao found the mice that ate an ionic copper 
supplemented diet had improved anti-proliferative effects by ascorbate on 
their human mammary xenografts (Tsao 1991). 
 
Interestingly, several studies have investigated a possible DNA 
damaging effect of ascorbate without mediation by transition metals, and 
have found cytotoxicity in metal-free cultures. Nappi et al. (Nappi and Vass 
2000) showed that ascorbate and hydrogen peroxide alone were capable of 
producing hydroxyl radicals within minutes, and more effectively than 
ascorbate-metal or metal-hydrogen peroxide complexes. In this case, 
ascorbate directly oxidises hydrogen peroxide to form water and the 
hydroxyl radical. 
 
AA + H2O2   AA. + H2O + .OH 
 
However, they did not use physiological concentrations of reactants 
in that study, thus its biological impact is unknown. It may be that this 
reaction is negligible compared to the creation of hydroxyl radicals in 
processes that do make use of catalytic metals. Certainly, the level of free 
metals seems to correlate with the degree of ROS creation. For example, in 
vitro, DMEM creates more hydrogen peroxide then RPMI, thought to be 
due to the extra 0.25 μM of Fe(NO3)3 (Clement, Ramalingam et al. 2001). 
 
A further interesting experiment could have been to test the H2AX 
and 8-OHdG markers for DNA damage with flow cytometry in metal free 
conditions. This could have been achieved with the same conditions as used 
in the comet tail assay, and treatment of cells in culture while in PBS rather 
than regular DMEM media. Another interesting possibility would have 
been to investigate metal supplementation of a subset of ascorbate treated 
mice, in order to ascertain any potential difference in tumour DNA damage 
outcomes. 
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The importance of metal also brings up a caveat to all experiments 
outlined here. Cell culture media age can affect the amount of trace metals 
present and so available during assays undertaken in media. In the assays 
presented here, cell culture DMEM and RPMI was made up in 500 mL 
volumes and used within a calendar month. It may be possible that this 
difference in media age at the time of any experiment played a part in 
varying rapidity of the creation of hydrogen peroxide from ascorbate and so 
altered results. 
Limitations 
To be expected, there are a number of caveats and limitations to 
bear in mind when assessing this investigation, in addition to those 
previously mentioned. 
 
The unique nature of the brain environment, enclosed by the blood 
brain barrier, with a high oxygen requirement and the particular 
characteristics of brain cells, prevents direct translation of data from papers 
that study cancers not in this environment. Unfortunately, much of the 
evidence that these experiments used as the foundation were not brain 
cancer or GBM, but were instead predominantly pancreatic, breast, or 
prostate cancers. In the same way, specific data from this study may not 
directly translate for scientists studying the effect of ascorbate in non-brain 
cancers. 
 
Another limitation is the inability to directly translate information 
derived from vivo models, such as those studied here, to the human context. 
Potential contrasts must be considered carefully before undertaking human 
clinical trials. Inevitably, there are large differences between artificially 
inoculated cancer in mice, to naturally occurring GBM in humans, which 
displays its own particular genetics. In fact, the differential cell response to 
identical treatments as seen here, is evidence that GL261s are by no means 
indistinguishable from human GBM. 
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Treatment application will also differ, complicating efforts to 
translate relevance. As mentioned, ascorbate given by parental infusion is 
considered a representative model of human intravenous injection. Yet, 
pharmacokinetic studies by Chen et al. (2007) showed that intravenous and 
intraperitoneal-delivered ascorbate concentrations, although they follow the 
same trend, are not entirely identical. Intravenous application, that used in 
human studies, causes higher ascorbate concentrations in the early time 
points than intraperitoneal, the method used in most rodent studies. Several 
millimoles’ difference was reported in peak plasma levels (3mM compared 
with 8mM plasma concentration) between the two methods. Because the 
subtleties of ascorbate’s effect at a given concentration has not been fully 
elucidated, it may eventually be determined that this difference makes a 
difference in ascorbate’s prooxidant effect. 
 
In this study, as with many other cancer research investigations, 
normal C57BL6 mice were used as murine models. However, in the context 
of ascorbate, they may not be the ideal treatment simulator. Mice, unlike 
humans and a small number of other organisms, can synthesise their own 
ascorbate, instead of having to consume it in the diet (see ‘Ascorbate as a 
Cofactor’). Although mice naturally do not synthesise the molecule to 
nearly the concentration expected to induce prooxidant effect, it is an extra 
complication with potential implications to results. Unfortunately, guinea 
pigs or GULO knockout mice were unavailable for research here. 
 
Interpretation of pharmacokinetic tests in healthy individuals, and 
how to relate this information to cancer patients is another caveat. Most 
pharmacokinetic research is based on healthy individuals, while studies in 
cancer patients generally do not directly measure the ascorbate to serum 
concentration correlation. It may be the case that cancer patients have 
altered absorption such that general pharmacokinetic conclusions are not 
relatable to their condition (Li and Schellhorn 2007). It may even be found 
that cancer patients, with their high requirements for ascorbic acid, deplete 
the systemic concentration such that remaining ascorbate acts as a 
traditional antioxidant, and serves to radio-protect cancer. 
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Because some trials have found that low doses of ascorbate increase 
the proliferation of cells (Riordan, Riordan et al. 1995), the specific 
concentration at which ascorbate transforms from an antioxidant to a 
prooxidant, and the conditions that influence this, should be carefully 
investigated. Despite widespread use of the molecule by alternative 
healthcare practitioners, it is not clear under precisely which conditions 
(concentration, tissue, amount of metals, transport) where the balance of its 
function shifts. 
 
It may also be that the nature of human serum itself is a limitation in 
being able to extrapolate from in vitro to in vivo data. Riordan et al. 
reported that introducing 20% human serum to culture medium attenuated 
the cytotoxic effects of ascorbate. 
Future Experiments 
Due to the time constraints, there are extra assays that may have 
been informative in this investigation, but were not possible, in addition to 
those mentioned previously in this discussion. They may be researched in 
the future in our lab. 
 
For instance, although already carried out in our lab on some 
measures of ascorbate’s effect, it would have been helpful to attempt a 
reversal of ascorbate’s prooxidant capacity with the hydrogen peroxide 
mitigating catalase, especially considering addition of hydrogen peroxide 
itself did not exactly correspond to ascorbate effect in the 8-OHdG assay. 
Catalase provokes the decomposition of H2O2 to water and oxygen. If 
catalase abrogated DNA damaging effect in the specific assays performed 
here, it would confirm peroxide mediation of this effect in a larger variety 
of types of damage. 
 
A further possibility might have been to investigate potential 
mechanisms of ascorbate’s cytotoxicity, such as the role of necrosis, 
apoptosis, autophagy or chromatin collapse, or some possible combination 
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of pathways for cell death. Thus far, some mechanisms have been 
investigated, but often contradict, due to some as yet unknown factors. It 
may also be that ascorbate’s cytotoxicity mechanism varies depending on 
ascorbate concentration, or whether it functions in conjunction with another 
DNA damaging agent.  
 
For in vivo application, it could have been informative to attempt 
different patterns of treatment other than short term (treatment on the day of 
harvest) versus longer term (treatment 24 hours prior to harvest). Although 
simplification in mouse studies is necessary for practicality, other regimens 
may have better represented human study. For example, a truly long term 
experiment may have been more representative of the treatment that human 
cancer patients go through, and include several treatments over the course 
of weeks. 
 
Ultimately, the most important next step in this area of research is to 
confirm ascorbate’s activity in vivo, where clinical relevance comes to the 
fore. If it is ineffective, it should be determined by which mechanism the in 
vitro efficacy is destroyed, and then if ineffectiveness is common under all 
or only some conditions, such as low oxygen. 
 
   *  *  *  
  
Conclusion 
In conclusion, GBM is a highly malignant brain cancer that has thus 
far eluded development of effective treatment. Traditional therapies such as 
radiation and chemotherapy fail to sufficiently extend lifespan, as such, 
investigations into potential therapy sensitizers are on-going. Ascorbate has 
long been proposed as a biologically plausible anti-cancer molecule due to 
its many faceted roles in anti-oxidation, catalysis, and prooxidation, and 
although in vitro results are plentiful, credible and consistent in vivo studies 
are lacking. Conflicting in vitro and in vivo outcomes from our lab 
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originally provoked this investigation, which aimed to focus on varieties of 
DNA damage in both contexts, and confirm or falsify the discrepancy. 
 
In vitro radiosensitisation evidence was validated by two assays, 
flow cytometry and the neutral comet tail assay, that measured three 
complementary markers designed to determine DNA damage; H2AX, a 
DNA damage-induced histone phosphorylation involved in the DNA 
damage response; 8-OHdG, a hydroxylation modification to the DNA base 
guanine that indicates oxidative damage, and DSBs, the most severe variant 
of DNA damage, and most likely to cause cell death. These assays were 
carried out on GL261s; a murine model of GBM, T98Gs; a human 
immortalised GBM cell line, and 1003s; a primary cell derived from ex 
vivo tumour tissue. 
 
Although results varied somewhat between these cell lines and 
assays, the broad in vitro trend was an increase in all markers of DNA 
damage in response to either 5 mM of ascorbate or 6 Gy of irradiation, but 
an even larger increase when cells received both treatments, confirmation 
of ascorbate’s radiosensitising function. 
 
In vivo experiments established intracranial GL261 model of GBM 
in C57BL6 mice and treated them with ascorbate, irradiation or both 
treatments before brain tumour and non-tumour tissue was harvested and 
underwent immunofluorescence. Two of the markers used on in vitro cells, 
H2AX and 8-OHdG, were assessed in images of both cancerous and 
normal brain, in brains of mice that were given each of the treatments.  
 
Although not fully optimised, the overall trend of in vivo data 
seemed to indicate that ascorbate does not supplement the effectiveness of 
irradiation in causing an increase in DNA damage, as indicated by H2AX 
or 8-OHdG. In fact, it may potentially decrease irradiation’s efficacy. 
Results were similar in cancerous and healthy tissue, and the sequence of 
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ascorbate pre or post irradiation did not appear to make an observable 
difference. 
 
Therefore, experiments detailed here show a credible 
radiosensitisation of GBM cells in vitro by ascorbate, as well as a potential 
radioprotective role for ascorbate in vivo. If confirmed, ascorbate treatment 
should be discontinued in patients also receiving radiation therapy, for it 
may lead, tragically, to shorter survival in an already deadly disease. 
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